228 results on '"Schmidt, Af"'
Search Results
2. Establishing reference intervals for triglyceride-containing lipoprotein subfraction metabolites measured using nuclear magnetic resonance spectroscopy in a UK population
- Author
-
Joshi, R, Wannamethee, G, Engmann, J, Gaunt, T, Lawlor, DA, Price, J, Papacosta, O, Shah, T, Tillin, T, Whincup, P, Chaturvedi, N, Kivimaki, M, Kuh, D, Kumari, M, Hughes, AD, Casas, JP, Humphries, SE, Hingorani, AD, Schmidt, AF, and UCLEB Consortium
- Abstract
BACKGROUND: Nuclear magnetic resonance (NMR) spectroscopy allows triglycerides to be subclassified into 14 different classes based on particle size and lipid content. We recently showed that these subfractions have differential associations with cardiovascular disease events. Here we report the distributions and define reference interval ranges for 14 triglyceride-containing lipoprotein subfraction metabolites. METHODS: Lipoprotein subfractions using the Nightingale NMR platform were measured in 9073 participants from four cohort studies contributing to the UCL-Edinburgh-Bristol consortium. The distribution of each metabolite was assessed, and reference interval ranges were calculated for a disease-free population, by sex and age group (65 years), and in a subgroup population of participants with cardiovascular disease or type 2 diabetes. We also determined the distribution across body mass index and smoking status. RESULTS: The largest reference interval range was observed in the medium very-low density lipoprotein subclass (2.5th 97.5th percentile; 0.08 to 0.68 mmol/L). The reference intervals were comparable among male and female participants, with the exception of triglyceride in high-density lipoprotein. Triglyceride subfraction concentrations in very-low density lipoprotein, intermediate-density lipoprotein, low-density lipoprotein and high-density lipoprotein subclasses increased with increasing age and increasing body mass index. Triglyceride subfraction concentrations were significantly higher in ever smokers compared to never smokers, among those with clinical chemistry measured total triglyceride greater than 1.7 mmol/L, and in those with cardiovascular disease, and type 2 diabetes as compared to disease-free subjects. CONCLUSION: This is the first study to establish reference interval ranges for 14 triglyceride-containing lipoprotein subfractions in samples from the general population measured using the nuclear magnetic resonance platform. The utility of nuclear magnetic resonance lipid measures may lead to greater insights for the role of triglyceride in cardiovascular disease, emphasizing the importance of appropriate reference interval ranges for future clinical decision making.
- Published
- 2021
3. Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events
- Author
-
Patel, RS, Schmidt, AF, Tragante, V, McCubrey, RO, Holmes, MV, Howe, LJ, Direk, K, Åkerblom, A, Leander, K, Virani, SS, Kaminski, KA, Muehlschlegel, JD, Dubé, M-P, Allayee, H, Almgren, P, Alver, M, Baranova, EV, Behlouli, H, Boeckx, B, Braund, PS, Breitling, LP, Delgado, G, Duarte, NE, Dufresne, L, Eriksson, N, Foco, L, Gijsberts, CM, Gong, Y, Hartiala, J, Heydarpour, M, Hubacek, JA, Kleber, M, Kofink, D, Kuukasjärvi, P, Lee, V-V, Leiherer, A, Lenzini, PA, Levin, D, Lyytikäinen, L-P, Martinelli, N, Mons, U, Nelson, CP, Nikus, K, Pilbrow, AP, Ploski, R, Sun, YV, Tanck, MWT, Tang, WHW, Trompet, S, Van Der Laan, SW, Van Setten, J, Vilmundarson, RO, Anselmi, C, Vlachopoulou, E, Boerwinkle, E, Briguori, C, Carlquist, JF, Carruthers, KF, Casu, G, Deanfield, J, Deloukas, P, Dudbridge, F, Fitzpatrick, N, Gigante, B, James, S, Lokki, M-L, Lotufo, PA, Marziliano, N, Mordi, IR, Muhlestein, JB, Newton-Cheh, C, Pitha, J, Saely, CH, Samman-Tahhan, A, Sandesara, PB, Teren, A, Timmis, A, Van De Werf, F, Wauters, E, Wilde, AAM, Ford, I, Stott, DJ, Algra, A, Andreassi, MG, Ardissino, D, Arsenault, BJ, Ballantyne, CM, Bergmeijer, TO, Bezzina, CR, Body, SC, Bogaty, P, De Borst, GJ, Brenner, H, Burkhardt, R, Carpeggiani, C, Condorelli, G, Cooper-Dehoff, RM, Cresci, S, De Faire, U, Doughty, RN, Drexel, H, Engert, JC, Fox, KAA, Girelli, D, Hagström, E, Hazen, SL, Held, C, Hemingway, H, Hoefer, IE, Hovingh, GK, Johnson, JA, De Jong, PA, Jukema, JW, Kaczor, MP, Kähönen, M, Kettner, J, Kiliszek, M, Klungel, OH, Lagerqvist, B, Lambrechts, D, Laurikka, JO, Lehtimäki, T, Lindholm, D, Mahmoodi, BK, Der Zee, AH, McPherson, R, Melander, O, Metspalu, A, Pepinski, W, Olivieri, O, Opolski, G, Palmer, CN, Pasterkamp, G, Pepine, CJ, Pereira, AC, Pilote, L, Quyyumi, AA, Richards, AM, Sanak, M, Scholz, M, Siegbahn, A, Sinisalo, J, Smith, JG, Spertus, JA, Stewart, AFR, Szczeklik, W, Szpakowicz, A, Berg, JM, Thanassoulis, G, Thiery, J, Van Der Graaf, Y, Visseren, FLJ, Waltenberger, J, Van Der Harst, P, Tardif, J-C, Sattar, N, Lang, CC, Paré, G, Brophy, JM, Anderson, JL, März, W, Wallentin, L, Cameron, VA, Horne, BD, Samani, NJ, Hingorani, AD, and Asselbergs, FW
- Subjects
Male ,Myocardial Infarction ,genetic risk factor ,Coronary Artery Disease ,Middle Aged ,Article ,chromosome 9p21 ,Gene Frequency ,Risk Factors ,Case-Control Studies ,Odds Ratio ,Humans ,Female ,Genetic Predisposition to Disease ,cardiovascular diseases ,Chromosomes, Human, Pair 9 ,secondary prevention - Abstract
Genetic variation at chromosome 9p21 is a recognized risk factor for coronary heart disease (CHD). However, its effect on disease progression and subsequent events is unclear, raising questions about its value for stratification of residual risk.A variant at chromosome 9p21 (rs1333049) was tested for association with subsequent events during follow-up in 103 357 Europeans with established CHD at baseline from the GENIUS-CHD (Genetics of Subsequent Coronary Heart Disease) Consortium (73.1% male, mean age 62.9 years). The primary outcome, subsequent CHD death or myocardial infarction (CHD death/myocardial infarction), occurred in 13 040 of the 93 115 participants with available outcome data. Effect estimates were compared with case/control risk obtained from the CARDIoGRAMplusC4D consortium (Coronary Artery Disease Genome-wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease [C4D] Genetics) including 47 222 CHD cases and 122 264 controls free of CHD.Meta-analyses revealed no significant association between chromosome 9p21 and the primary outcome of CHD death/myocardial infarction among those with established CHD at baseline (GENIUS-CHD odds ratio, 1.02; 95% CI, 0.99-1.05). This contrasted with a strong association in CARDIoGRAMPlusC4D odds ratio 1.20; 95% CI, 1.18-1.22; P for interaction0.001 compared with the GENIUS-CHD estimate. Similarly, no clear associations were identified for additional subsequent outcomes, including all-cause death, although we found a modest positive association between chromosome 9p21 and subsequent revascularization (odds ratio, 1.07; 95% CI, 1.04-1.09).In contrast to studies comparing individuals with CHD to disease-free controls, we found no clear association between genetic variation at chromosome 9p21 and risk of subsequent acute CHD events when all individuals had CHD at baseline. However, the association with subsequent revascularization may support the postulated mechanism of chromosome 9p21 for promoting atheroma development.
- Published
- 2019
4. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
- Author
-
Schmidt, AF, Holmes, MV, Preiss, D, Swerdlow, DI, Denaxas, S, Fatemifar, G, Pazoki, Raha, Franco Duran, OH, Hofman, Bert, Uitterlinden, André, Dehghan, Abbas, Sonneveld, Pieter, Casas, JP, Hingorani, AD, Schmidt, AF, Holmes, MV, Preiss, D, Swerdlow, DI, Denaxas, S, Fatemifar, G, Pazoki, Raha, Franco Duran, OH, Hofman, Bert, Uitterlinden, André, Dehghan, Abbas, Sonneveld, Pieter, Casas, JP, and Hingorani, AD
- Published
- 2019
5. Subsequent Event Risk in Individuals With Established Coronary Heart Disease Design and Rationale of the GENIUS-CHD Consortium
- Author
-
Patel, RS, Tragante, V, Schmidt, AF, McCubrey, RO, Holmes, MV, Howe, LJ, Boersma, Eric, Brugts, Jasper, Hingorani, AD, Asselbergs, FW, Patel, RS, Tragante, V, Schmidt, AF, McCubrey, RO, Holmes, MV, Howe, LJ, Boersma, Eric, Brugts, Jasper, Hingorani, AD, and Asselbergs, FW
- Published
- 2019
6. Comparison of variance estimators for meta-analysis of instrumental variable estimates
- Author
-
Schmidt, AF, Hingorani, AD, Jefferis, BJ, White, J, Groenwold, RHH, and Dudbridge, F
- Subjects
Bias ,Meta-Analysis as Topic ,Epidemiology methods ,statistics ,Data Interpretation, Statistical ,Mendelian randomization analysis ,Mendelian Randomisation and Instrumental Variable Analysis ,Humans ,Computer Simulation - Abstract
Background: Mendelian randomization studies perform instrumental variable (IV) analysis using genetic IVs. Results of individual Mendelian randomization studies can be pooled through meta-analysis. We explored how different variance estimators influence the meta-analysed IV estimate. Methods: Two versions of the delta method (IV before or after pooling), four bootstrap estimators, a jack-knife estimator and a heteroscedasticity-consistent (HC) variance estimator were compared using simulation. Two types of meta-analyses were compared, a two-stage meta-analysis pooling results, and a one-stage meta-analysis pooling datasets. Results: Using a two-stage meta-analysis, coverage of the point estimate using bootstrapped estimators deviated from nominal levels at weak instrument settings and/or outcome probabilities ≤ 0.10. The jack-knife estimator was the least biased resampling method, the HC estimator often failed at outcome probabilities ≤ 0.50 and overall the delta method estimators were the least biased. In the presence of between-study heterogeneity, the delta method before meta-analysis performed best. Using a one-stage meta-analysis all methods performed equally well and better than two-stage meta-analysis of greater or equal size. Conclusions: In the presence of between-study heterogeneity, two-stage meta-analyses should preferentially use the delta method before meta-analysis. Weak instrument bias can be reduced by performing a one-stage meta-analysis.
- Published
- 2016
7. An electronic health records cohort study on heart failure following myocardial infarction in England: incidence and predictors
- Author
-
Gho, JMIH, Schmidt, AF, Pasea, L, Koudstaal, K, Pujades-Rodriguez, M, Denaxas, S, Shah, AD, Patel, RS, Gale, CP, Hoes, AW, Cleland, JG, Hemingway, H, Asselbergs, FW, PharmacoTherapy, -Epidemiology and -Economics, and Bedi, H
- Subjects
Male ,MILLION PEOPLE ,heart failure ,Cohort Studies ,READMISSION ,Risk Factors ,Atrial Fibrillation ,GENERAL-PRACTICE ,Diabetes Mellitus ,Humans ,SOCIOECONOMIC-STATUS ,Registries ,Aged ,RISK ,Medicine(all) ,Incidence ,Research ,MORTALITY ,PRIMARY-CARE ,Correction ,Middle Aged ,R1 ,Survival Analysis ,TRENDS ,electronic health records ,myocardial infarction ,England ,Socioeconomic Factors ,Hypertension ,Multivariate Analysis ,CARDIOVASCULAR-DISEASES ,Female ,General practice / Family practice ,PRACTICE RESEARCH DATABASE ,Biomarkers - Abstract
Objectives: To investigate the incidence and determinants of heart failure (HF) following a myocardial infarction (MI) in a contemporary cohort of patients with MI using routinely collected primary and hospital care electronic health records (EHRs).\ud \ud \ud \ud Methods: Data were used from the CALIBER programme, linking EHRs in England from primary care, hospital admissions, an MI registry and mortality data. Subjects were eligible if they were 18 years or older, did not have a history of HF and survived a first MI. Factors associated with time to HF were examined using Cox proportional hazard models.\ud \ud \ud \ud Results: Of the 24 479 patients with MI, 5775 (23.6%) developed HF during a median follow-up of 3.7 years (incidence rate per 1000 person-years: 63.8, 95% CI 62.2 to 65.5). Baseline characteristics significantly associated with developing HF were: atrial fibrillation (HR 1.62, 95% CI 1.51 to 1.75), age (per 10 years increase: 1.45, 1.41 to 1.49), diabetes (1.45, 1.35 to 1.56), peripheral arterial disease (1.38, 1.26 to 1.51), chronic obstructive pulmonary disease (1.28, 1.17 to 1.40), greater socioeconomic deprivation (5th vs 1st quintile: 1.27, 1.13 to 1.41), ST-segment elevation MI at presentation (1.19, 1.11 to 1.27) and hypertension (1.16, 1.09 to 1.23). Results were robust to various sensitivity analyses such as competing risk analysis and multiple imputation.\ud \ud \ud \ud Conclusion: In England, one in four survivors of a first MI develop HF within 4 years. This contemporary study demonstrates that patients with MI are at considerable risk of HF. Baseline patient characteristics associated with time until HF were identified, which may be used to target preventive strategies.
- Published
- 2018
- Full Text
- View/download PDF
8. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- Author
-
Schmidt, AF, Swerdlow, DI, Holmes, MV, Patel, RS, Fairhurst-Hunter, Z, Lyall, DM, Hartwig, FP, Horta, BL, Hypponen, E, Power, C, Moldovan, M, van Iperen, E, Hovingh, GK, Demuth, I, Norman, K, Steinhagen-Thiessen, E, Demuth, J, Bertram, L, Liu, T, Coassin, S, Willeit, J, Kiechl, S, Willeit, K, Mason, D, Wright, J, Morris, R, Wanamethee, G, Whincup, P, Ben-Shlomo, Y, McLachlan, S, Price, JF, Kivimaki, M, Welch, C, Sanchez-Galvez, A, Marques-Vidal, P, Nicolaides, A, Panayiotou, AG, Onland-Moret, NC, van der Schouw, YT, Matullo, G, Fiorito, G, Guarrera, S, Sacerdote, C, Wareham, NJ, Langenberg, C, Scott, R, Luan, JA, Bobak, M, Malyutina, SA, Pajak, A, Kubinova, R, Tamosiunas, A, Pikhart, H, Husemoen, LLN, Grarup, N, Pedersen, O, Hansen, T, Linneberg, A, Simonsen, KS, Cooper, J, Humphries, SE, Brilliant, M, Kitchner, T, Hakonarson, H, Carrell, DS, McCarty, CA, Kirchner, HL, Larson, EB, Crosslin, DR, de Andrade, M, Roden, DM, Denny, JC, Carty, C, Hancock, S, Attia, J, Holliday, E, Donnell, MO, Yusuf, S, Chong, M, Pare, G, van der Harst, P, Said, MA, Eppinga, RN, Verweij, N, Snieder, H, Christen, T, Mook-Kanamori, DO, Gustafsson, S, Lind, L, Ingelsson, E, Pazoki, Raha, Franco Duran, OH, Hofman, Bert, Uitterlinden, André, Dehghan, Abbas, Teumer, A, Baumeister, S, Dorr, M, Lerch, MM, Volker, U, Volzke, H, Ward, J, Pell, JP, Smith, Derek, Meade, T, Zee, AH, Baranova, EV, Young, R, Ford, I, Campbell, A (Archie), Padmanabhan, S, Bots, ML, Grobbee, DE, Froguel, P, Thuillier, D, Balkau, B, Bonnefond, A, Cariou, B, Smart, M, Bao, Y, Kumari, M, Mahajan, A, Ridker, PM, Chasman, DI, Reiner, AP, Lange, LA, Ritchie, MD, Asselbergs, FW, Casas, JP, Keating, BJ, Preiss, D, Hingorani, AD, Sattar, N, Schmidt, AF, Swerdlow, DI, Holmes, MV, Patel, RS, Fairhurst-Hunter, Z, Lyall, DM, Hartwig, FP, Horta, BL, Hypponen, E, Power, C, Moldovan, M, van Iperen, E, Hovingh, GK, Demuth, I, Norman, K, Steinhagen-Thiessen, E, Demuth, J, Bertram, L, Liu, T, Coassin, S, Willeit, J, Kiechl, S, Willeit, K, Mason, D, Wright, J, Morris, R, Wanamethee, G, Whincup, P, Ben-Shlomo, Y, McLachlan, S, Price, JF, Kivimaki, M, Welch, C, Sanchez-Galvez, A, Marques-Vidal, P, Nicolaides, A, Panayiotou, AG, Onland-Moret, NC, van der Schouw, YT, Matullo, G, Fiorito, G, Guarrera, S, Sacerdote, C, Wareham, NJ, Langenberg, C, Scott, R, Luan, JA, Bobak, M, Malyutina, SA, Pajak, A, Kubinova, R, Tamosiunas, A, Pikhart, H, Husemoen, LLN, Grarup, N, Pedersen, O, Hansen, T, Linneberg, A, Simonsen, KS, Cooper, J, Humphries, SE, Brilliant, M, Kitchner, T, Hakonarson, H, Carrell, DS, McCarty, CA, Kirchner, HL, Larson, EB, Crosslin, DR, de Andrade, M, Roden, DM, Denny, JC, Carty, C, Hancock, S, Attia, J, Holliday, E, Donnell, MO, Yusuf, S, Chong, M, Pare, G, van der Harst, P, Said, MA, Eppinga, RN, Verweij, N, Snieder, H, Christen, T, Mook-Kanamori, DO, Gustafsson, S, Lind, L, Ingelsson, E, Pazoki, Raha, Franco Duran, OH, Hofman, Bert, Uitterlinden, André, Dehghan, Abbas, Teumer, A, Baumeister, S, Dorr, M, Lerch, MM, Volker, U, Volzke, H, Ward, J, Pell, JP, Smith, Derek, Meade, T, Zee, AH, Baranova, EV, Young, R, Ford, I, Campbell, A (Archie), Padmanabhan, S, Bots, ML, Grobbee, DE, Froguel, P, Thuillier, D, Balkau, B, Bonnefond, A, Cariou, B, Smart, M, Bao, Y, Kumari, M, Mahajan, A, Ridker, PM, Chasman, DI, Reiner, AP, Lange, LA, Ritchie, MD, Asselbergs, FW, Casas, JP, Keating, BJ, Preiss, D, Hingorani, AD, and Sattar, N
- Published
- 2017
9. Multiplicity dependence of pion, kaon, proton and lambda production in p-Pb collisions at √SNN = 5.02 TeV
- Author
-
B. Abelev bq, J. Adam aj, D. Adamová by, A. M. Adare dv, M. M. Aggarwal cc, G. Aglieri Rinella ag, M. Agnello ci, A. G. Agocs du, A. Agostinelli y, Z. Ahammed dq, N. Ahmad p, A. Ahmad Masoodi p, I. Ahmed n, S. U. Ahn bj, S. A. Ahn bj, I. Aimo cz, S. Aiola dv, M. Ajaz n, A. Akindinov ba, D. Aleksandrov co, B. Alessandro cz, D. Alexandre cq, A. Alici k, A. Alkin c, J. Alme ah, T. Alt al, V. Altini ad, S. Altinpinar q, I. Altsybeev dp, C. Alves Garcia Prado dg, C. Andrei bt, A. Andronic cl, V. Anguelov ch, J. Anielski av, T. Anticˇic ́ cm, F. Antinori cw, P. Antonioli ct, L. Aphecetche da, H. Appelshäuser at, N. Arbor bm, S. Arcelli y, N. Armesto o, R. Arnaldi cz, T. Aronsson dv, I. C. Arsene cl, M. Arslandok at, A. Augustinus ag, R. Averbeck cl, T. C. Awes bz, M. D. Azmi ce, M. Bach al, A. Badalà cv, Y. W. Baek bl, R. Bailhache at, V. Bairathi cg, R. Bala cz, A. Baldisseri m, F. Baltasar Dos Santos Pedrosa ag, J. Bán bb, R. C. Baral bd, R. Barbera z, F. Barile ad, G. G. Barnaföldi du, L. S. Barnby cq, V. Barret bl, J. Bartke dd, M. Basile y, N. Bastid bl, S. Basu dq, B. Bathen av, G. Batigne da, B. Batyunya bi, P. C. Batzing t, C. Baumann at, I. G. Bearden bv, H. Beck at, N. K. Behera ap, I. Belikov aw, F. Bellini y, R. Bellwied di, E. Belmont Moreno bg, G. Bencedi du, S. Beole w, I. Berceanu bt, A. Bercuci bt, Y. Berdnikov ca, D. Berenyi du, A. A. E. Bergognon da, R. A. Bertens az, D. Berzano w, L. Betev ag, A. Bhasin cf, A. K. Bhati cc, J. Bhom dm, L. Bianchi w, N. Bianchi bn, J. Bielcˇík aj, J. Bielcˇíková by, A. Bilandzic bv, S. Bjelogrlic az, F. Blanco i, F. Blanco di, D. Blau co, C. Blume at, F. Bock bp, A. Bogdanov br, H. Bøggild bv, M. Bogolyubsky ax, L. Boldizsár du, M. Bombara ak, J. Book at, H. Borel m, A. Borissov dt, J. Bornschein al, M. Botje bw, E. Botta w, S. Böttger as, P. Braun Munzinger cl, M. Bregant da, T. Breitner as, T. A. Broker at, T. A. Browning cj, M. Broz ai, R. Brun ag, E. Bruna cz, G. E. Bruno ad, D. Budnikov cn, H. Buesching at, S. Bufalino cz, P. Buncic ag, O. Busch ch, Z. Buthelezi bh, D. Caffarri aa, X. Cai f, H. Caines dv, A. Caliva az, E. Calvo Villar cr, V. Canoa Roman j, G. Cara Romeo ct, F. Carena ag, W. Carena ag, F. Carminati ag, A. Casanova Díaz bn, J. Castillo Castellanos m, E. A. R. Casula u, V. Catanescu bt, C. Cavicchioli ag, C. Ceballos Sanchez h, J. Cepila aj, P. Cerello cz, B. Chang dj, S. Chapeland ag, J. L. Charvet m, S. Chattopadhyay dq, S. Chattopadhyay cp, M. Cherney cb, C. Cheshkov do, B. Cheynis do, V. Chibante Barroso ag, D. D. Chinellato di, P. Chochula ag, M. Chojnacki bv, S. Choudhury dq, P. Christakoglou bw, C. H. Christensen bv, P. Christiansen ae, T. Chujo dm, S. U. Chung ck, C. Cicalo cu, L. Cifarelli k, y, F. Cindolo ct, J. Cleymans ce, F. Colamaria ad, D. Colella ad, A. Collu u, M. Colocci y, G. Conesa Balbastre bm, Z. Conesa del Valle ar, M. E. Connors dv, G. Contin v, J. G. Contreras j, T. M. Cormier dt, Y. Corrales Morales w, P. Cortese ac, I. Cortés Maldonado b, M. R. Cosentino bp, F. Costa ag, P. Crochet bl, R. Cruz Albino j, E. Cuautle bf, L. Cunqueiro bn, A. Dainese cw, R. Dang f, A. Danu be, K. Das cp, D. Das cp, I. Das ar, A. Dash dh, S. Dash ap, S. De dq, H. Delagrange da, A. Deloff bs, E. Dénes du, A. Deppman dg, G. O. V. de Barros dg, A. De Caro k, G. de Cataldo cs, J. de Cuveland al, A. De Falco u, D. De Gruttola ab, k, N. De Marco cz, S. De Pasquale ab, R. de Rooij az, M. A. Diaz Corchero i, T. Dietel av, R. Divià ag, D. Di Bari ad, C. Di Giglio ad, S. Di Liberto cx, A. Di Mauro ag, P. Di Nezza bn, Ø. Djuvsland q, A. Dobrin az, T. Dobrowolski bs, B. Dönigus cl, O. Dordic t, A. K. Dubey dq, A. Dubla az, L. Ducroux do, P. Dupieux bl, A. K. Dutta Majumdar cp, G. D. Erasmo ad, D. Elia cs, D. Emschermann av, H. Engel as, B. Erazmus ag, H. A. Erdal ah, D. Eschweiler al, B. Espagnon ar, M. Estienne da, S. Esumi dm, D. Evans cq, S. Evdokimov ax, G. Eyyubova t, D. Fabris cw, J. Faivre bm, D. Falchieri y, A. Fantoni bn, M. Fasel ch, D. Fehlker q, L. Feldkamp av, D. Felea be, A. Feliciello cz, G. Feofilov dp, J. Ferencei by, A. Fernández Téllez b, E. G. Ferreiro o, A. Ferretti w, A. Festanti aa, J. Figiel dd, M. A. S. Figueredo dg, S. Filchagin cn, D. Finogeev ay, F. M. Fionda ad, E. M. Fiore ad, E. Floratos cd, M. Floris ag, S. Foertsch bh, P. Foka cl, S. Fokin co, A. Francescon aa, U. Frankenfeld cl, U. Fuchs ag, C. Furget bm, M. Fusco Girard ab, J. J. Gaardhøje bv, M. Gagliardi w, A. Gago cr, M. Gallio w, D. R. Gangadharan r, P. Ganoti bz, C. Garabatos cl, E. Garcia Solis l, C. Gargiulo ag, I. Garishvili bq, J. Gerhard al, M. Germain da, A. Gheata ag, M. Gheata ag, B. Ghidini ad, P. Ghosh dq, P. Gianotti bn, P. Giubellino ag, E. Gladysz Dziadus dd, P. Glässel ch, L. Goerlich dd, R. Gomez j, P. González Zamora i, S. Gorbunov al, S. Gotovac dc, L. K. Graczykowski ds, R. Grajcarek ch, A. Grelli az, C. Grigoras ag, A. Grigoras ag, V. Grigoriev br, A. Grigoryan a, S. Grigoryan bi, B. Grinyov c, N. Grion cy, J. F. Grosse Oetringhaus ag, J. Y. Grossiord do, R. Grosso ag, F. Guber ay, R. Guernane bm, B. Guerzoni y, M. Guilbaud do, K. Gulbrandsen bv, H. Gulkanyan a, T. Gunji dl, A. Gupta cf, R. Gupta cf, K. H. Khan n, R. Haake av, Ø. Haaland q, C. Hadjidakis ar, M. Haiduc be, H. Hamagaki dl, G. Hamar du, L. D. Hanratty cq, A. Hansen bv, J. W. Harris dv, H. Hartmann al, A. Harton l, D. Hatzifotiadou ct, S. Hayashi dl, A. Hayrapetyan ag, a, S. T. Heckel at, M. Heide av, H. Helstrup ah, A. Herghelegiu bt, G. Herrera Corral j, N. Herrmann ch, B. A. Hess af, K. F. Hetland ah, B. Hicks dv, B. Hippolyte aw, Y. Hori dl, P. Hristov ag, I. Hrˇivnácˇová ar, M. Huang q, T. J. Humanic r, D. Hutter al, D. S. Hwang s, R. Ilkaev cn, I. Ilkiv bs, M. Inaba dm, E. Incani u, G. M. Innocenti w, C. Ionita ag, M. Ippolitov co, M. Irfan p, M. Ivanov cl, V. Ivanov ca, O. Ivanytskyi c, A. Jachołkowski z, P. M. Jacobs bp, C. Jahnke dg, H. J. Jang bj, M. A. Janik ds, P. H. S. Y. Jayarathna di, S. Jena ap, R. T. Jimenez Bustamante bf, P. G. Jones cq, H. Jung am, A. Jusko cq, S. Kalcher al, P. Kalinˇák bb, A. Kalweit ag, J. H. Kang dw, V. Kaplin br, S. Kar dq, A. Karasu Uysal bk, O. Karavichev ay, T. Karavicheva ay, E. Karpechev ay, A. Kazantsev co, U. Kebschull as, R. Keidel dx, B. Ketzer at, M. M. Khan p, P. Khan cp, S. A. Khan dq, A. Khanzadeev ca, Y. Kharlov ax, B. Kileng ah, T. Kim dw, B. Kim dw, D. J. Kim dj, D. W. Kim am, J. S. Kim am, M. Kim am, M. Kim dw, S. Kim s, S. Kirsch al, I. Kisel al, S. Kiselev ba, A. Kisiel ds, G. Kiss du, J. L. Klay e, J. Klein ch, C. Klein Bösing av, A. Kluge ag, M. L. Knichel cl, A. G. Knospe de, C. Kobdaj ag, M. K. Köhler cl, T. Kollegger al, A. Kolojvari dp, V. Kondratiev dp, N. Kondratyeva br, A. Konevskikh ay, V. Kovalenko dp, M. Kowalski dd, S. Kox bm, G. Koyithatta Meethaleveedu ap, J. Kral dj, I. Králik bb, F. Kramer at, A. Kravcˇáková ak, M. Krelina aj, M. Kretz al, M. Krivda bb, F. Krizek aj, by, an, M. Krus aj, E. Kryshen ca, M. Krzewicki cl, V. Kucera by, Y. Kucheriaev co, T. Kugathasan ag, C. Kuhn aw, P. G. Kuijer bw, I. Kulakov at, J. Kumar ap, P. Kurashvili bs, A. B. Kurepin ay, A. Kurepin ay, A. Kuryakin cn, V. Kushpil by, S. Kushpil by, M. J. Kweon ch, Y. Kwon dw, P. Ladrón de Guevara bf, C. Lagana Fernandes dg, I. Lakomov ar, R. Langoy dr, C. Lara as, A. Lardeux da, A. Lattuca w, S. L. La Pointe az, P. La Rocca z, M. Lechman ag, S. C. Lee am, G. R. Lee cq, I. Legrand ag, J. Lehnert at, R. C. Lemmon bx, M. Lenhardt cl, V. Lenti cs, M. Leoncino w, I. León Monzón df, P. Lévai du, S. Li bl, f, J. Lien dr, q, R. Lietava cq, S. Lindal t, V. Lindenstruth al, C. Lippmann cl, M. A. Lisa r, H. M. Ljunggren ae, D. F. Lodato az, P. I. Loenne q, V. R. Loggins dt, V. Loginov br, D. Lohner ch, C. Loizides bp, X. Lopez bl, E. López Torres h, G. Løvhøiden t, X. G. Lu ch, P. Luettig at, M. Lunardon aa, J. Luo f, C. Luzzi ag, R. Ma dv, A. Maevskaya ay, M. Mager ag, D. P. Mahapatra bd, A. Maire ch, M. Malaev ca, I. Maldonado Cervantes bf, L. Malinina bi, 1, D. Mal’Kevich ba, P. Malzacher cl, A. Mamonov cn, L. Manceau cz, V. Manko co, F. Manso bl, V. Manzari cs, M. Marchisone bl, w, J. Mareš bc, A. Margotti ct, A. Marín cl, C. Markert de, M. Marquard at, I. Martashvili dk, N. A. Martin cl, P. Martinengo ag, M. I. Martínez b, G. Martínez García da, J. Martin Blanco da, Y. Martynov c, A. Mas da, S. Masciocchi cl, M. Masera w, A. Masoni cu, L. Massacrier da, A. Mastroserio ad, A. Matyja dd, J. Mazer dk, R. Mazumder aq, M. A. Mazzoni cx, F. Meddi x, A. Menchaca Rocha bg, J. Mercado Pérez ch, M. Meres ai, Y. Miake dm, K. Mikhaylov bi, L. Milano ag, J. Milosevic t, 2, A. Mischke az, A. N. Mishra aq, D. Mis ́kowiec cl, C. Mitu be, J. Mlynarz dt, B. Mohanty dq, L. Molnar aw, L. Montaño Zetina j, M. Monteno cz, E. Montes i, M. Morando aa, D. A. Moreira De Godoy dg, S. Moretto aa, A. Morreale dj, A. Morsch ag, V. Muccifora bn, E. Mudnic dc, S. Muhuri dq, M. Mukherjee dq, H. Müller ag, M. G. Munhoz dg, S. Murray bh, L. Musa ag, B. K. Nandi ap, R. Nania ct, E. Nappi cs, C. Nattrass dk, T. K. Nayak dq, S. Nazarenko cn, A. Nedosekin ba, M. Nicassio cl, M. Niculescu ag, B. S. Nielsen bv, S. Nikolaev co, S. Nikulin co, V. Nikulin ca, B. S. Nilsen cb, M. S. Nilsson t, F. Noferini k, P. Nomokonov bi, G. Nooren az, A. Nyanin co, A. Nyatha ap, J. Nystrand q, H. Oeschler ch, S. K. Oh am, 3, S. Oh dv, L. Olah du, J. Oleniacz ds, A. C. Oliveira Da Silva dg, J. Onderwaater cl, C. Oppedisano cz, A. Ortiz Velasquez ae, A. Oskarsson ae, J. Otwinowski cl, K. Oyama ch, Y. Pachmayer ch, M. Pachr aj, P. Pagano ab, G. Paic ́ bf, F. Painke al, C. Pajares o, S. K. Pal dq, A. Palaha cq, A. Palmeri cv, V. Papikyan a, G. S. Pappalardo cv, W. J. Park cl, A. Passfeld av, D. I. Patalakha ax, V. Paticchio cs, B. Paul cp, T. Pawlak ds, T. Peitzmann az, H. Pereira Da Costa m, E. Pereira De Oliveira Filho dg, D. Peresunko co, C. E. Pérez Lara bw, D. Perrino ad, W. Peryt ds, 4, A. Pesci ct, Y. Pestov d, V. Petrácˇek aj, M. Petran aj, M. Petris bt, P. Petrov cq, M. Petrovici bt, C. Petta z, M. Pikna ai, P. Pillot da, O. Pinazza ag, L. Pinsky di, N. Pitz at, D. B. Piyarathna di, M. Planinic dn, M. Płoskon ́ bp, J. Pluta ds, S. Pochybova du, P. L. M. Podesta Lerma df, M. G. Poghosyan ag, B. Polichtchouk ax, A. Pop bt, S. Porteboeuf Houssais bl, V. Pospíšil aj, B. Potukuchi cf, S. K. Prasad dt, R. Preghenella k, F. Prino cz, C. A. Pruneau dt, I. Pshenichnov ay, G. Puddu u, V. Punin cn, J. Putschke dt, H. Qvigstad t, A. Rachevski cy, A. Rademakers ag, J. Rak dj, A. Rakotozafindrabe m, L. Ramello ac, S. Raniwala cg, R. Raniwala cg, S. S. Räsänen an, B. T. Rascanu at, D. Rathee cc, W. Rauch ag, A. W. Rauf n, V. Razazi u, K. F. Read dk, J. S. Real bm, K. Redlich bs, 5, R. J. Reed dv, A. Rehman q, P. Reichelt at, M. Reicher az, F. Reidt ag, R. Renfordt at, A. R. Reolon bn, A. Reshetin ay, F. Rettig al, J. P. Revol ag, K. Reygers ch, L. Riccati cz, R. A. Ricci bo, T. Richert ae, M. Richter t, P. Riedler ag, W. Riegler ag, F. Riggi z, A. Rivetti cz, M. Rodríguez Cahuantzi b, A. Rodriguez Manso bw, K. Røed q, t, E. Rogochaya bi, S. Rohni cf, D. Rohr al, D. Röhrich q, R. Romita bx, F. Ronchetti bn, P. Rosnet bl, S. Rossegger ag, A. Rossi ag, P. Roy cp, C. Roy aw, A. J. Rubio Montero i, R. Russo w, E. Ryabinkin co, A. Rybicki dd, S. Sadovsky ax, K. Šafarˇík ag, R. Sahoo aq, P. K. Sahu bd, J. Saini dq, H. Sakaguchi ao, S. Sakai bp, D. Sakata dm, C. A. Salgado o, J. Salzwedel r, S. Sambyal cf, V. Samsonov ca, X. Sanchez Castro bf, L. Šándor bb, A. Sandoval bg, M. Sano dm, G. Santagati z, R. Santoro k, D. Sarkar dq, E. Scapparone ct, F. Scarlassara aa, R. P. Scharenberg cj, C. Schiaua bt, R. Schicker ch, C. Schmidt cl, H. R. Schmidt af, S. Schuchmann at, J. Schukraft ag, M. Schulc aj, T. Schuster dv, Y. Schutz ag, K. Schwarz cl, K. Schweda cl, G. Scioli y, E. Scomparin cz, R. Scott dk, P. A. Scott cq, G. Segato aa, I. Selyuzhenkov cl, J. Seo ck, S. Serci u, E. Serradilla i, A. Sevcenco be, A. Shabetai da, G. Shabratova bi, R. Shahoyan ag, S. Sharma cf, N. Sharma dk, K. Shigaki ao, K. Shtejer h, Y. Sibiriak co, S. Siddhanta cu, T. Siemiarczuk bs, D. Silvermyr bz, C. Silvestre bm, G. Simatovic dn, R. Singaraju dq, R. Singh cf, S. Singha dq, V. Singhal dq, B. C. Sinha dq, T. Sinha cp, B. Sitar ai, M. Sitta ac, T. B. Skaali t, K. Skjerdal q, R. Smakal aj, N. Smirnov dv, R. J. M. Snellings az, R. Soltz bq, M. Song dw, J. Song ck, C. Soos ag, F. Soramel aa, M. Spacek aj, I. Sputowska dd, M. Spyropoulou Stassinaki cd, B. K. Srivastava cj, J. Stachel ch, I. Stan be, G. Stefanek bs, M. Steinpreis r, E. Stenlund ae, G. Steyn bh, J. H. Stiller ch, D. Stocco da, M. Stolpovskiy ax, P. Strmen ai, A. A. P. Suaide dg, M. A. Subieta Vásquez w, T. Sugitate ao, C. Suire ar, M. Suleymanov n, R. Sultanov ba, M. Šumbera by, T. Susa cm, T. J. M. Symons bp, A. Szanto de Toledo dg, I. Szarka ai, A. Szczepankiewicz ag, M. Szyman ́ ski ds, J. Takahashi dh, M. A. Tangaro ad, J. D. Tapia Takaki ar, A. Tarantola Peloni at, A. Tarazona Martinez ag, A. Tauro ag, G. Tejeda Muñoz b, A. Telesca ag, C. Terrevoli ad, A. Ter Minasyan co, J. Thäder cl, D. Thomas az, R. Tieulent do, A. R. Timmins di, A. Toia cw, H. Torii dl, V. Trubnikov c, W. H. Trzaska dj, T. Tsuji dl, A. Tumkin cn, R. Turrisi cw, T. S. Tveter t, J. Ulery at, K. Ullaland q, J. Ulrich as, A. Uras do, G. M. Urciuoli cx, G. L. Usai u, M. Vajzer by, M. Vala bb, L. Valencia Palomo ar, P. Vande Vyvre ag, L. Vannucci bo, J. W. Van Hoorne ag, M. van Leeuwen az, A. Vargas b, R. Varma ap, M. Vasileiou cd, A. Vasiliev co, V. Vechernin dp, M. Veldhoen az, M. Venaruzzo v, E. Vercellin w, S. Vergara b, R. Vernet g, M. Verweij dt, L. Vickovic dc, G. Viesti aa, J. Viinikainen dj, Z. Vilakazi bh, O. Villalobos Baillie cq, A. Vinogradov co, L. Vinogradov dp, Y. Vinogradov cn, T. Virgili ab, Y. P. Viyogi dq, A. Vodopyanov bi, M. A. Völkl ch, S. Voloshin dt, K. Voloshin ba, G. Volpe ag, B. von Haller ag, I. Vorobyev dp, D. Vranic ag, J. Vrláková ak, B. Vulpescu bl, A. Vyushin cn, B. Wagner q, V. Wagner aj, J. Wagner cl, Y. Wang ch, Y. Wang f, M. Wang f, D. Watanabe dm, K. Watanabe dm, M. Weber di, J. P. Wessels av, U. Westerhoff av, J. Wiechula af, J. Wikne t, M. Wilde av, G. Wilk bs, J. Wilkinson ch, M. C. S. Williams ct, B. Windelband ch, M. Winn ch, C. Xiang f, C. G. Yaldo dt, Y. Yamaguchi dl, H. Yang m, P. Yang f, S. Yang q, S. Yano ao, S. Yasnopolskiy co, J. Yi ck, Z. Yin f, I. K. Yoo ck, I. Yushmanov co, V. Zaccolo bv, C. Zach aj, C. Zampolli ct, S. Zaporozhets bi, A. Zarochentsev dp, P. Závada bc, N. Zaviyalov cn, H. Zbroszczyk ds, P. Zelnicek as, I. S. Zgura be, M. Zhalov ca, F. Zhangf, Y. Zhangf, H. Zhangf, X. Zhangbp, bl, f, D. Zhouf, Y. Zhouaz, F. Zhouf, X. Zhuf, J. Zhuf, H. Zhu f, A. Zichichi k, M. B. Zimmermann av, A. Zimmermann ch, G. Zinovjev c, Y. Zoccarato do, M. Zynovyev c, M. Zyzak, CONTIN, GIACOMO, CAMERINI, Paolo, FRAGIACOMO, ENRICO, LEA, RAMONA, LUPARELLO, GRAZIA, MARGAGLIOTTI, GIACOMO, PIANO, STEFANO, RUI, RINALDO, B., Abelev bq, J., Adam aj, D., Adamová by, A. M., Adare dv, M. M., Aggarwal cc, G., Aglieri Rinella ag, M., Agnello ci, Cz, A. G., Agocs du, A., Agostinelli y, Z., Ahammed dq, N., Ahmad p, A., Ahmad Masoodi p, I., Ahmed n, S. U., Ahn bj, S. A., Ahn bj, I., Aimo cz, Ci, S., Aiola dv, M., Ajaz n, A., Akindinov ba, D., Aleksandrov co, B., Alessandro cz, D., Alexandre cq, A., Alici k, Ct, A., Alkin c, J., Alme ah, T., Alt al, V., Altini ad, S., Altinpinar q, I., Altsybeev dp, C., Alves Garcia Prado dg, C., Andrei bt, A., Andronic cl, V., Anguelov ch, J., Anielski av, T., Anticˇic ́ cm, F., Antinori cw, P., Antonioli ct, L., Aphecetche da, H., Appelshäuser at, N., Arbor bm, S., Arcelli y, N., Armesto o, R., Arnaldi cz, T., Aronsson dv, I. C., Arsene cl, M., Arslandok at, A., Augustinus ag, R., Averbeck cl, T. C., Awes bz, M. D., Azmi ce, M., Bach al, A., Badalà cv, Y. W., Baek bl, Am, R., Bailhache at, V., Bairathi cg, R., Bala cz, Cf, A., Baldisseri m, F., Baltasar Dos Santos Pedrosa ag, J., Bán bb, R. C., Baral bd, R., Barbera z, F., Barile ad, G. G., Barnaföldi du, L. S., Barnby cq, V., Barret bl, J., Bartke dd, M., Basile y, N., Bastid bl, S., Basu dq, B., Bathen av, G., Batigne da, B., Batyunya bi, P. C., Batzing t, C., Baumann at, I. G., Bearden bv, H., Beck at, N. K., Behera ap, I., Belikov aw, F., Bellini y, R., Bellwied di, E., Belmont Moreno bg, G., Bencedi du, S., Beole w, I., Berceanu bt, A., Bercuci bt, Y., Berdnikov ca, D., Berenyi du, A. A. E., Bergognon da, R. A., Bertens az, D., Berzano w, L., Betev ag, A., Bhasin cf, A. K., Bhati cc, J., Bhom dm, L., Bianchi w, N., Bianchi bn, J., Bielcˇík aj, J., Bielcˇíková by, A., Bilandzic bv, S., Bjelogrlic az, F., Blanco i, F., Blanco di, D., Blau co, C., Blume at, F., Bock bp, Ch, A., Bogdanov br, H., Bøggild bv, M., Bogolyubsky ax, L., Boldizsár du, M., Bombara ak, J., Book at, H., Borel m, A., Borissov dt, J., Bornschein al, M., Botje bw, E., Botta w, S., Böttger a, P., Braun Munzinger cl, M., Bregant da, T., Breitner a, T. A., Broker at, T. A., Browning cj, M., Broz ai, R., Brun ag, E., Bruna cz, G. E., Bruno ad, D., Budnikov cn, H., Buesching at, S., Bufalino cz, P., Buncic ag, O., Busch ch, Z., Buthelezi bh, D., Caffarri aa, X., Cai f, H., Caines dv, A., Caliva az, E., Calvo Villar cr, Camerini, Paolo, V., Canoa Roman j, Ag, G., Cara Romeo ct, F., Carena ag, W., Carena ag, F., Carminati ag, A., Casanova Díaz bn, J., Castillo Castellanos m, E. A. R., Casula u, V., Catanescu bt, C., Cavicchioli ag, C., Ceballos Sanchez h, J., Cepila aj, P., Cerello cz, B., Chang dj, S., Chapeland ag, J. L., Charvet m, S., Chattopadhyay dq, S., Chattopadhyay cp, M., Cherney cb, C., Cheshkov do, B., Cheynis do, V., Chibante Barroso ag, D. D., Chinellato di, P., Chochula ag, M., Chojnacki bv, S., Choudhury dq, P., Christakoglou bw, C. H., Christensen bv, P., Christiansen ae, T., Chujo dm, S. U., Chung ck, C., Cicalo cu, L., Cifarelli k, Y, F., Cindolo ct, J., Cleymans ce, F., Colamaria ad, D., Colella ad, A., Collu u, M., Colocci y, G., Conesa Balbastre bm, Z., Conesa del Valle ar, M. E., Connors dv, G., Contin v, J. G., Contreras j, T. M., Cormier dt, Y., Corrales Morales w, P., Cortese ac, I., Cortés Maldonado b, M. R., Cosentino bp, F., Costa ag, P., Crochet bl, R., Cruz Albino j, E., Cuautle bf, L., Cunqueiro bn, A., Dainese cw, R., Dang f, A., Danu be, K., Das cp, D., Das cp, I., Das ar, A., Dash dh, S., Dash ap, S., De dq, H., Delagrange da, A., Deloff b, E., Dénes du, A., Deppman dg, G. O. V., de Barros dg, A., De Caro k, Ab, G., de Cataldo c, J., de Cuveland al, A., De Falco u, D., De Gruttola ab, K, N., De Marco cz, S., De Pasquale ab, R., de Rooij az, M. A., Diaz Corchero i, T., Dietel av, R., Divià ag, D., Di Bari ad, C., Di Giglio ad, S., Di Liberto cx, A., Di Mauro ag, P., Di Nezza bn, Ø., Djuvsland q, A., Dobrin az, Dt, T., Dobrowolski b, B., Dönigus cl, At, O., Dordic t, A. K., Dubey dq, A., Dubla az, L., Ducroux do, P., Dupieux bl, A. K., Dutta Majumdar cp, G. D., Erasmo ad, D., Elia c, D., Emschermann av, H., Engel a, B., Erazmus ag, Da, H. A., Erdal ah, D., Eschweiler al, B., Espagnon ar, M., Estienne da, S., Esumi dm, D., Evans cq, S., Evdokimov ax, G., Eyyubova t, D., Fabris cw, J., Faivre bm, D., Falchieri y, A., Fantoni bn, M., Fasel ch, D., Fehlker q, L., Feldkamp av, D., Felea be, A., Feliciello cz, G., Feofilov dp, J., Ferencei by, A., Fernández Téllez b, E. G., Ferreiro o, A., Ferretti w, A., Festanti aa, J., Figiel dd, M. A. S., Figueredo dg, S., Filchagin cn, D., Finogeev ay, F. M., Fionda ad, E. M., Fiore ad, E., Floratos cd, M., Floris ag, S., Foertsch bh, P., Foka cl, S., Fokin co, Fragiacomo, Enrico, A., Francescon aa, U., Frankenfeld cl, U., Fuchs ag, C., Furget bm, M., Fusco Girard ab, J. J., Gaardhøje bv, M., Gagliardi w, A., Gago cr, M., Gallio w, D. R., Gangadharan r, P., Ganoti bz, C., Garabatos cl, E., Garcia Solis l, C., Gargiulo ag, I., Garishvili bq, J., Gerhard al, M., Germain da, A., Gheata ag, M., Gheata ag, Be, B., Ghidini ad, P., Ghosh dq, P., Gianotti bn, P., Giubellino ag, E., Gladysz Dziadus dd, P., Glässel ch, L., Goerlich dd, R., Gomez j, Df, P., González Zamora i, S., Gorbunov al, S., Gotovac dc, L. K., Graczykowski d, R., Grajcarek ch, A., Grelli az, C., Grigoras ag, A., Grigoras ag, V., Grigoriev br, A., Grigoryan a, S., Grigoryan bi, B., Grinyov c, N., Grion cy, J. F., Grosse Oetringhaus ag, J. Y., Grossiord do, R., Grosso ag, F., Guber ay, R., Guernane bm, B., Guerzoni y, M., Guilbaud do, K., Gulbrandsen bv, H., Gulkanyan a, T., Gunji dl, A., Gupta cf, R., Gupta cf, K. H., Khan n, R., Haake av, Ø., Haaland q, C., Hadjidakis ar, M., Haiduc be, H., Hamagaki dl, G., Hamar du, L. D., Hanratty cq, A., Hansen bv, J. W., Harris dv, H., Hartmann al, A., Harton l, D., Hatzifotiadou ct, S., Hayashi dl, A., Hayrapetyan ag, A, S. T., Heckel at, M., Heide av, H., Helstrup ah, A., Herghelegiu bt, G., Herrera Corral j, N., Herrmann ch, B. A., Hess af, K. F., Hetland ah, B., Hicks dv, B., Hippolyte aw, Y., Hori dl, P., Hristov ag, I., Hrˇivnácˇová ar, M., Huang q, T. J., Humanic r, D., Hutter al, D. S., Hwang, R., Ilkaev cn, I., Ilkiv b, M., Inaba dm, E., Incani u, G. M., Innocenti w, C., Ionita ag, M., Ippolitov co, M., Irfan p, M., Ivanov cl, V., Ivanov ca, O., Ivanytskyi c, A., Jachołkowski z, P. M., Jacobs bp, C., Jahnke dg, H. J., Jang bj, M. A., Janik d, P. H. S. Y., Jayarathna di, S., Jena ap, Di, R. T., Jimenez Bustamante bf, P. G., Jones cq, H., Jung am, A., Jusko cq, S., Kalcher al, P., Kalinˇák bb, A., Kalweit ag, J. H., Kang dw, V., Kaplin br, S., Kar dq, A., Karasu Uysal bk, O., Karavichev ay, T., Karavicheva ay, E., Karpechev ay, A., Kazantsev co, U., Kebschull a, R., Keidel dx, B., Ketzer at, M. M., Khan p, P., Khan cp, S. A., Khan dq, A., Khanzadeev ca, Y., Kharlov ax, B., Kileng ah, T., Kim dw, B., Kim dw, D. J., Kim dj, D. W., Kim am, Bj, J. S., Kim am, M., Kim am, M., Kim dw, S., Kim, S., Kirsch al, I., Kisel al, S., Kiselev ba, A., Kisiel d, G., Kiss du, J. L., Klay e, J., Klein ch, C., Klein Bösing av, A., Kluge ag, M. L., Knichel cl, A. G., Knospe de, C., Kobdaj ag, Db, M. K., Köhler cl, T., Kollegger al, A., Kolojvari dp, V., Kondratiev dp, N., Kondratyeva br, A., Konevskikh ay, V., Kovalenko dp, M., Kowalski dd, S., Kox bm, G., Koyithatta Meethaleveedu ap, J., Kral dj, I., Králik bb, F., Kramer at, A., Kravcˇáková ak, M., Krelina aj, M., Kretz al, M., Krivda bb, Cq, F., Krizek aj, By, An, M., Krus aj, E., Kryshen ca, M., Krzewicki cl, V., Kucera by, Y., Kucheriaev co, T., Kugathasan ag, C., Kuhn aw, P. G., Kuijer bw, I., Kulakov at, J., Kumar ap, P., Kurashvili b, A. B., Kurepin ay, A., Kurepin ay, A., Kuryakin cn, V., Kushpil by, S., Kushpil by, M. J., Kweon ch, Y., Kwon dw, P., Ladrón de Guevara bf, C., Lagana Fernandes dg, I., Lakomov ar, R., Langoy dr, C., Lara a, A., Lardeux da, A., Lattuca w, S. L., La Pointe az, P., La Rocca z, Lea, Ramona, M., Lechman ag, S. C., Lee am, G. R., Lee cq, I., Legrand ag, J., Lehnert at, R. C., Lemmon bx, M., Lenhardt cl, V., Lenti c, M., Leoncino w, I., León Monzón df, P., Lévai du, S., Li bl, F, J., Lien dr, Q, R., Lietava cq, S., Lindal t, V., Lindenstruth al, C., Lippmann cl, M. A., Lisa r, H. M., Ljunggren ae, D. F., Lodato az, P. I., Loenne q, V. R., Loggins dt, V., Loginov br, D., Lohner ch, C., Loizides bp, X., Lopez bl, E., López Torres h, G., Løvhøiden t, X. G., Lu ch, P., Luettig at, M., Lunardon aa, J., Luo f, Luparello, Grazia, C., Luzzi ag, R., Ma dv, A., Maevskaya ay, M., Mager ag, D. P., Mahapatra bd, A., Maire ch, M., Malaev ca, I., Maldonado Cervantes bf, L., Malinina bi, D., Mal’Kevich ba, P., Malzacher cl, A., Mamonov cn, L., Manceau cz, V., Manko co, F., Manso bl, V., Manzari c, M., Marchisone bl, W, J., Mareš bc, Margagliotti, Giacomo, A., Margotti ct, A., Marín cl, C., Markert de, M., Marquard at, I., Martashvili dk, N. A., Martin cl, P., Martinengo ag, M. I., Martínez b, G., Martínez García da, J., Martin Blanco da, Y., Martynov c, A., Mas da, S., Masciocchi cl, M., Masera w, A., Masoni cu, L., Massacrier da, A., Mastroserio ad, A., Matyja dd, J., Mazer dk, R., Mazumder aq, M. A., Mazzoni cx, F., Meddi x, A., Menchaca Rocha bg, J., Mercado Pérez ch, M., Meres ai, Y., Miake dm, K., Mikhaylov bi, Ba, L., Milano ag, J., Milosevic t, A., Mischke az, A. N., Mishra aq, D., Mis ́kowiec cl, C., Mitu be, J., Mlynarz dt, B., Mohanty dq, Bu, L., Molnar aw, Du, L., Montaño Zetina j, M., Monteno cz, E., Montes i, M., Morando aa, D. A., Moreira De Godoy dg, S., Moretto aa, A., Morreale dj, A., Morsch ag, V., Muccifora bn, E., Mudnic dc, S., Muhuri dq, M., Mukherjee dq, H., Müller ag, M. G., Munhoz dg, S., Murray bh, L., Musa ag, B. K., Nandi ap, R., Nania ct, E., Nappi c, C., Nattrass dk, T. K., Nayak dq, S., Nazarenko cn, A., Nedosekin ba, M., Nicassio cl, Ad, M., Niculescu ag, B. S., Nielsen bv, S., Nikolaev co, S., Nikulin co, V., Nikulin ca, B. S., Nilsen cb, M. S., Nilsson t, F., Noferini k, P., Nomokonov bi, G., Nooren az, A., Nyanin co, A., Nyatha ap, J., Nystrand q, H., Oeschler ch, Au, S. K., Oh am, S., Oh dv, L., Olah du, J., Oleniacz d, A. C., Oliveira Da Silva dg, J., Onderwaater cl, C., Oppedisano cz, A., Ortiz Velasquez ae, A., Oskarsson ae, J., Otwinowski cl, K., Oyama ch, Y., Pachmayer ch, M., Pachr aj, P., Pagano ab, G., Paic ́ bf, F., Painke al, C., Pajares o, S. K., Pal dq, A., Palaha cq, A., Palmeri cv, V., Papikyan a, G. S., Pappalardo cv, W. J., Park cl, A., Passfeld av, D. I., Patalakha ax, V., Paticchio c, B., Paul cp, T., Pawlak d, T., Peitzmann az, H., Pereira Da Costa m, E., Pereira De Oliveira Filho dg, D., Peresunko co, C. E., Pérez Lara bw, D., Perrino ad, W., Peryt d, A., Pesci ct, Y., Pestov d, V., Petrácˇek aj, M., Petran aj, M., Petris bt, P., Petrov cq, M., Petrovici bt, C., Petta z, Piano, Stefano, M., Pikna ai, P., Pillot da, O., Pinazza ag, L., Pinsky di, N., Pitz at, D. B., Piyarathna di, M., Planinic dn, Cm, M., Płoskon ́ bp, J., Pluta d, S., Pochybova du, P. L. M., Podesta Lerma df, M. G., Poghosyan ag, B., Polichtchouk ax, A., Pop bt, S., Porteboeuf Houssais bl, V., Pospíšil aj, B., Potukuchi cf, S. K., Prasad dt, R., Preghenella k, F., Prino cz, C. A., Pruneau dt, I., Pshenichnov ay, G., Puddu u, V., Punin cn, J., Putschke dt, H., Qvigstad t, A., Rachevski cy, A., Rademakers ag, J., Rak dj, A., Rakotozafindrabe m, L., Ramello ac, S., Raniwala cg, R., Raniwala cg, S. S., Räsänen an, B. T., Rascanu at, D., Rathee cc, W., Rauch ag, A. W., Rauf n, V., Razazi u, K. F., Read dk, J. S., Real bm, K., Redlich b, R. J., Reed dv, A., Rehman q, P., Reichelt at, M., Reicher az, F., Reidt ag, R., Renfordt at, A. R., Reolon bn, A., Reshetin ay, F., Rettig al, J. P., Revol ag, K., Reygers ch, L., Riccati cz, R. A., Ricci bo, T., Richert ae, M., Richter t, P., Riedler ag, W., Riegler ag, F., Riggi z, A., Rivetti cz, M., Rodríguez Cahuantzi b, A., Rodriguez Manso bw, K., Røed q, T, E., Rogochaya bi, S., Rohni cf, D., Rohr al, D., Röhrich q, R., Romita bx, Cl, F., Ronchetti bn, P., Rosnet bl, S., Rossegger ag, A., Rossi ag, P., Roy cp, C., Roy aw, A. J., Rubio Montero i, Rui, Rinaldo, R., Russo w, E., Ryabinkin co, A., Rybicki dd, S., Sadovsky ax, K., Šafarˇík ag, R., Sahoo aq, P. K., Sahu bd, J., Saini dq, H., Sakaguchi ao, S., Sakai bp, Bn, D., Sakata dm, C. A., Salgado o, J., Salzwedel r, S., Sambyal cf, V., Samsonov ca, X., Sanchez Castro bf, Aw, L., Šándor bb, A., Sandoval bg, M., Sano dm, G., Santagati z, R., Santoro k, D., Sarkar dq, E., Scapparone ct, F., Scarlassara aa, R. P., Scharenberg cj, C., Schiaua bt, R., Schicker ch, C., Schmidt cl, H. R., Schmidt af, S., Schuchmann at, J., Schukraft ag, M., Schulc aj, T., Schuster dv, Y., Schutz ag, K., Schwarz cl, K., Schweda cl, G., Scioli y, E., Scomparin cz, R., Scott dk, P. A., Scott cq, G., Segato aa, I., Selyuzhenkov cl, J., Seo ck, S., Serci u, E., Serradilla i, Bg, A., Sevcenco be, A., Shabetai da, G., Shabratova bi, R., Shahoyan ag, S., Sharma cf, N., Sharma dk, K., Shigaki ao, K., Shtejer h, Y., Sibiriak co, S., Siddhanta cu, T., Siemiarczuk b, D., Silvermyr bz, C., Silvestre bm, G., Simatovic dn, R., Singaraju dq, R., Singh cf, S., Singha dq, V., Singhal dq, B. C., Sinha dq, T., Sinha cp, B., Sitar ai, M., Sitta ac, T. B., Skaali t, K., Skjerdal q, R., Smakal aj, N., Smirnov dv, R. J. M., Snellings az, R., Soltz bq, M., Song dw, J., Song ck, C., Soos ag, F., Soramel aa, M., Spacek aj, I., Sputowska dd, M., Spyropoulou Stassinaki cd, B. K., Srivastava cj, J., Stachel ch, I., Stan be, G., Stefanek b, M., Steinpreis r, E., Stenlund ae, G., Steyn bh, J. H., Stiller ch, D., Stocco da, M., Stolpovskiy ax, P., Strmen ai, A. A. P., Suaide dg, M. A., Subieta Vásquez w, T., Sugitate ao, C., Suire ar, M., Suleymanov n, R., Sultanov ba, M., Šumbera by, T., Susa cm, T. J. M., Symons bp, A., Szanto de Toledo dg, I., Szarka ai, A., Szczepankiewicz ag, M., Szyman ́ ski d, J., Takahashi dh, M. A., Tangaro ad, J. D., Tapia Takaki ar, A., Tarantola Peloni at, A., Tarazona Martinez ag, A., Tauro ag, G., Tejeda Muñoz b, A., Telesca ag, C., Terrevoli ad, A., Ter Minasyan co, Br, J., Thäder cl, D., Thomas az, R., Tieulent do, A. R., Timmins di, A., Toia cw, H., Torii dl, V., Trubnikov c, W. H., Trzaska dj, T., Tsuji dl, A., Tumkin cn, R., Turrisi cw, T. S., Tveter t, J., Ulery at, K., Ullaland q, J., Ulrich a, A., Uras do, G. M., Urciuoli cx, G. L., Usai u, M., Vajzer by, M., Vala bb, Bi, L., Valencia Palomo ar, P., Vande Vyvre ag, L., Vannucci bo, J. W., Van Hoorne ag, M., van Leeuwen az, A., Vargas b, R., Varma ap, M., Vasileiou cd, A., Vasiliev co, V., Vechernin dp, M., Veldhoen az, M., Venaruzzo v, E., Vercellin w, S., Vergara b, R., Vernet g, M., Verweij dt, Az, L., Vickovic dc, G., Viesti aa, J., Viinikainen dj, Z., Vilakazi bh, O., Villalobos Baillie cq, A., Vinogradov co, L., Vinogradov dp, Y., Vinogradov cn, T., Virgili ab, Y. P., Viyogi dq, A., Vodopyanov bi, M. A., Völkl ch, S., Voloshin dt, K., Voloshin ba, G., Volpe ag, B., von Haller ag, I., Vorobyev dp, D., Vranic ag, J., Vrláková ak, B., Vulpescu bl, A., Vyushin cn, B., Wagner q, V., Wagner aj, J., Wagner cl, Y., Wang ch, Y., Wang f, M., Wang f, D., Watanabe dm, K., Watanabe dm, M., Weber di, J. P., Wessels av, U., Westerhoff av, J., Wiechula af, J., Wikne t, M., Wilde av, G., Wilk b, J., Wilkinson ch, M. C. S., Williams ct, B., Windelband ch, M., Winn ch, C., Xiang f, C. G., Yaldo dt, Y., Yamaguchi dl, H., Yang m, P., Yang f, S., Yang q, S., Yano ao, S., Yasnopolskiy co, J., Yi ck, Z., Yin f, I. K., Yoo ck, I., Yushmanov co, Zaccolo bv, V., C., Zach aj, C., Zampolli ct, S., Zaporozhets bi, A., Zarochentsev dp, P., Závada bc, N., Zaviyalov cn, H., Zbroszczyk d, P., Zelnicek a, I. S., Zgura be, M., Zhalov ca, F., Zhangf, Y., Zhangf, H., Zhangf, X., Zhangbp, Bl, F, D., Zhouf, Y., Zhouaz, F., Zhouf, X., Zhuf, J., Zhuf, H., Zhu f, A., Zichichi k, M. B., Zimmermann av, A., Zimmermann ch, G., Zinovjev c, Y., Zoccarato do, M., Zynovyev c, M., Zyzak, and Contin, Giacomo
- Subjects
hadron production ,p-Pb collisions ,Multiplicity ,Multiplicity dependence ,p-Pb collision ,5.02 TeV ,Nuclear Experiment - Abstract
Inthis Letter, comprehensive results on π±,K±,K0S, p(pbar) and Λ(Λbar) production at mid-rapidity (0< yCMS < 0.5) in p–Pb collisions at √sNN = 5.02 TeV, measured by the ALICE detector at the LHC, are reported. The transverse momentum distributions exhibit a hardening as a function of event multiplicity, which is stronger for heavier particles. This behavior is similar to what has been observed in pp and Pb–Pb collisions at the LHC. The measured pT distributions are compared to d–Au, Au–Au and Pb–Pb results at lower energy and with predictions based on QCD-inspired and hydrodynamic models.
- Published
- 2014
10. Adjusting for bias in unblinded randomized controlled trials
- Author
-
Schmidt, AF, primary and Groenwold, RHH, additional
- Published
- 2016
- Full Text
- View/download PDF
11. Prognostic factors of early metastasis and mortality in dogs with appendicular osteosarcoma after receiving surgery: an individual patient data meta-analysis
- Author
-
Schmidt, Af, Nielen, M, Klungel, O, Hoes, Aw, de Boer, A, Groenwold, Rhh, Kirpensteijn, J, Amsellem, P, Bacon, N, Berg, J, Kow, K, Kurzman, I, Maritato, K, Moore, A, Morello, Emanuela Maria, Sottnik, J, and Vail, D.
- Subjects
proportional hazards model ,bone tumor ,Metastasis ,Food Animals ,animal ,genetics ,Dog Diseases ,disease free survival ,Hazard ratio ,Age Factors ,article ,biological marker ,female ,multivariate analysis ,risk factor ,dog ,oncology ,Osteosarcoma ,alkaline phosphatase ,medicine.medical_specialty ,sex difference ,canine ,Bone Neoplasms ,Canine Osteosarcoma ,survival ,body weight ,Dogs ,Sex Factors ,male ,blood ,osteosarcoma ,medicine ,Adjuvant therapy ,Animals ,metastasis ,Risk factor ,dog disease ,Proportional Hazards Models ,Proportional hazards model ,business.industry ,Cancer ,medicine.disease ,mortality ,Surgery ,age ,Animal Science and Zoology ,pathology ,business ,animal disease ,Biomarkers ,neoplasm ,meta analysis - Abstract
Recently an aggregated data meta-analysis showed that serum alkaline phosphatase (SALP) and proximal humerus location are predictors for shorter survival in canine osteosarcoma. To identify additional prognostic factors of mortality and metastasis an individual patient data meta-analysis (IPDMA) was conducted. Individual patient data from 20 studies, identified via the VSSO society, were pooled. Univariable and multivariable hazard ratios (HR) for metastasis and mortality were assessed, using stratified Cox models. The study included 1405 dogs who received surgical treatment, of which the metastasis status was measured in 1155 dogs and mortality status in 1336 dogs; median survival was 256 days. High versus normal SALP and weight (kg) were associated with an increase in hazard of metastasis [HR 1.34 (95%CI 1.07; 1.68) and HR 1.02 (per kg increase) (95%CI 1.01; 1.03)] and for mortality [HR 1.43 (95%CI 1.16; 1.77) and HR 1.02 (95%CI 1.01; 1.02)]. Distal radius tumor was associated with a lower hazard of metastasis compared to other locations: HR 0.75 (95%CI 0.58; 0.96). Proximal humerus and distal femur or proximal tibia location were related with an increased mortality: HR 1.53 (95%CI 1.26; 1.84) and HR 1.23 (95%CI 1.01; 1.49) compared to other locations. Older age (years) was associated with a higher hazard for mortality [HR 1.06 per year (95%CI 1.03; 1.09)] but not for metastasis: HR 1.03 (95%CI 0.99; 1.06). These results confirm findings from a recent aggregated data meta-analysis and (in addition) showed that tumor location, SALP, weight were prognostic factors for both mortality and metastasis. Age was a prognostic factor for mortality but not for metastasis. © 2013 Elsevier B.V.
- Published
- 2013
12. Evaluation of histological changes after tracheal occlusion at different gestational ages in a fetal rat model
- Author
-
Gallindo, RM, primary, Goncalves, FL, additional, Barreto, CT, additional, Schmidt, AF, additional, Pereira, LA, additional, and Sbragia, L, additional
- Published
- 2013
- Full Text
- View/download PDF
13. Zusammenhang zwischen selbst gesetzten Therapiezielen und Therapieergebnis bei stationären Cannabis-/Partydrogenpatienten
- Author
-
Dau, W, primary, Scholz, JS, additional, Schmidt, A, additional, Schmidt, AF, additional, and Banger, M, additional
- Published
- 2011
- Full Text
- View/download PDF
14. Om Fjärsingens Stik og Giftredskaber1)
- Author
-
SCHMIDT, Af Professor Or. F. T., primary
- Published
- 2009
- Full Text
- View/download PDF
15. Evaluation of Nitric Oxide (NO) and Nitric Oxide Synthases (NOS) in the Amniotic Fluid in an Experimental Gastroschisis Rat Model.
- Author
-
Gonçalves FL, de Souza GF, Schmidt AF, Regis AC, de Oliveira MG, and Sbragia L
- Published
- 2011
16. Assessment of the expression of IR[beta], IRS-1, IRS-2 and IGF-IR[beta] in a rat model of intrauterine growth restriction.
- Author
-
Bueno MP, Guadagnini D, Gonçalves FL, Barini R, Saad MJ, Schmidt AF, and Sbragia L
- Published
- 2010
- Full Text
- View/download PDF
17. Om Fjärsingens Stik og Giftredskaber1).
- Author
-
SCHMIDT, Af Professor Or. F. T.
- Published
- 1874
- Full Text
- View/download PDF
18. Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis
- Author
-
Lotta, LA, Scott, RA, Sharp, SJ, Burgess, S, Luan, J, Tillin, T, Schmidt, AF, Imamura, F, Stewart, ID, Perry, JRB, Marney, L, Koulman, A, Karoly, ED, Forouhi, NG, Sjögren, RJO, Näslund, E, Zierath, Krook, A, Savage, DB, Griffin, JL, Chaturvedi, N, Hingorani, AD, Khaw, K-T, Barroso, I, McCarthy, MI, O'Rahilly, S, Wareham, NJ, and Langenberg, C
- Subjects
Adult ,Male ,Sweden ,Mendelian Randomization Analysis ,Middle Aged ,3. Good health ,Young Adult ,Diabetes Mellitus, Type 2 ,Risk Factors ,Humans ,Genetic Predisposition to Disease ,Prospective Studies ,Amino Acids, Branched-Chain ,Aged ,Genome-Wide Association Study - Abstract
$\textbf{BACKGROUND}$: Higher circulating levels of the branched-chain amino acids (BCAAs; i.e., isoleucine, leucine, and valine) are strongly associated with higher type 2 diabetes risk, but it is not known whether this association is causal. We undertook large-scale human genetic analyses to address this question. $\textbf{METHODS AND FINDINGS}$: Genome-wide studies of BCAA levels in 16,596 individuals revealed five genomic regions associated at genome-wide levels of significance (p < 5 × 10-8). The strongest signal was 21 kb upstream of the PPM1K gene (beta in standard deviations [SDs] of leucine per allele = 0.08, p = 3.9 × 10-25), encoding an activator of the mitochondrial branched-chain alpha-ketoacid dehydrogenase (BCKD) responsible for the rate-limiting step in BCAA catabolism. In another analysis, in up to 47,877 cases of type 2 diabetes and 267,694 controls, a genetically predicted difference of 1 SD in amino acid level was associated with an odds ratio for type 2 diabetes of 1.44 (95% CI 1.26-1.65, p = 9.5 × 10-8) for isoleucine, 1.85 (95% CI 1.41-2.42, p = 7.3 × 10-6) for leucine, and 1.54 (95% CI 1.28-1.84, p = 4.2 × 10-6) for valine. Estimates were highly consistent with those from prospective observational studies of the association between BCAA levels and incident type 2 diabetes in a meta-analysis of 1,992 cases and 4,319 non-cases. Metabolome-wide association analyses of BCAA-raising alleles revealed high specificity to the BCAA pathway and an accumulation of metabolites upstream of branched-chain alpha-ketoacid oxidation, consistent with reduced BCKD activity. Limitations of this study are that, while the association of genetic variants appeared highly specific, the possibility of pleiotropic associations cannot be entirely excluded. Similar to other complex phenotypes, genetic scores used in the study captured a limited proportion of the heritability in BCAA levels. Therefore, it is possible that only some of the mechanisms that increase BCAA levels or affect BCAA metabolism are implicated in type 2 diabetes. $\textbf{CONCLUSIONS}$: Evidence from this large-scale human genetic and metabolomic study is consistent with a causal role of BCAA metabolism in the aetiology of type 2 diabetes.
19. Cancer incidence and mortality among patients with new-onset atrial fibrillation: A population-based matched cohort study.
- Author
-
Zakkak N, Barclay M, Gonzalez-Izquierdo A, Schmidt AF, Lip GYH, Lyratzopoulos G, and Providencia R
- Abstract
Background: Understanding the risk of cancer after the diagnosis of another condition can present opportunities for earlier diagnosis. We examined the risk of cancer diagnosis conditional on prior diagnosis of atrial fibrillation (AF)., Methods: Linked electronic health records were used to identify patients aged ≥18 with new-onset AF and age-sex-matched controls. Cumulative incidence of and mortality from cancer (overall and cancer-site specific) within three months, three months to five years and beyond five years from diagnosis of AF were examined. Findings were further validated using Mendelian randomisation (MR)., Results: The cohort included 117,173 patients with new-onset AF and 117,173 matched controls (median age 78). In the first three months, 2.2% of AF patients were diagnosed with cancer vs. 0.47% in controls (relative risk: 4.7 [95%CI 4.2-5.4] in men and 4.4 [95%CI 3.8-5.0] in women). Nearly 80% of cancers related to thoracic or abdominal organs. Differences in cumulative incidence were only evident in women between three months and five years (subdistribution hazard ratio=1.1 [95%CI 1.01-1.12]) and absent in all patients beyond five years. MR analysis did not support the presence of a causal association between AF and major cancer subtypes., Conclusion: There is a large short-term increase in cancer incidence and mortality following new-onset AF. The findings may reflect incidental identification of AF or paraneoplastic manifestation. New-onset AF confers high short-term risk of cancer diagnosis, at levels comparable with symptomatic risk threshold mandating urgent assessment for suspected cancer., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. GYHL is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 899871., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
20. Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion?
- Author
-
Yoshimura H, Providencia R, Finan C, Schmidt AF, and Lip GYH
- Subjects
- Humans, Female, Male, Risk Assessment, Aged, Sex Factors, Aged, 80 and over, Risk Factors, United Kingdom epidemiology, Stroke epidemiology, Middle Aged, Anticoagulants therapeutic use, Atrial Fibrillation epidemiology, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy, Thromboembolism epidemiology, Thromboembolism prevention & control
- Abstract
Aims: The CHA2DS2VASc score is recommended for stroke risk stratification in patients with atrial fibrillation (AF). This score assigns one extra point to female sex based on evidence from the early 2000s, suggesting higher thromboembolic risk in women. This incremental risk of thromboembolism in women has decreased over time between 2007 and 2018, becoming non-significant in recent years. The objective of this study was to assess the impact of removing the sex category (Sc) from the CHA2DS2VASc score, thus validating a non-sex CHA2DS2VASc (i.e. CHA2DS2VA) score., Methods and Results: We analysed UK primary and secondary care data comprising 195 719 patients with AF followed between 1998 and 2016 (mean age: 75.9 ± 12.3 years; 49.2% women). Among 126 428 non-anticoagulated patients, we compared the CHA2DS2VASc vs. CHA2DS2VA scores every calendar year. Throughout 413 007 patient-years, a total of 8742 events of ischaemic stroke or systemic embolism were recorded. Sex differences in thromboembolic risk were not observed in the lower-risk population, but higher stroke rates were consistently seen in female patients in the higher-risk category (i.e. CHA2DS2VA ≥2). C-statistics for both CHA2DS2VA and CHA2DS2VASc scores were similar over the years (ranging from 0.62 to 0.71). With CHA2DS2VA, no relevant differences were observed in integrated discrimination improvement, and net reclassification improvement (NRI) resulted in improved reclassification (11%) in lower thromboembolic risk groups. The NRI suggested misclassification in higher thromboembolic risk patients (-7%), but this did not affect their indication for anticoagulation (i.e. patients retained their high-risk status)., Conclusion: Removing Sc from the CHA2DS2VASc score does not affect its ability to discriminate thromboembolic events in the population with AF. The use of CHA2DS2VA may simplify initial decision-making for thromboprophylaxis., Competing Interests: Conflict of interest: G.Y.H.L. is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Anthos. No fees were received personally. The remaining authors have no other conflicts of interest to declare., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
21. Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation.
- Author
-
van Vugt M, Finan C, Chopade S, Providencia R, Bezzina CR, Asselbergs FW, van Setten J, and Schmidt AF
- Subjects
- Humans, Mendelian Randomization Analysis, Metabolome, Molecular Targeted Therapy, Biomarkers, Male, Female, Atrial Fibrillation metabolism, Atrial Fibrillation drug therapy, Proteomics methods, Metabolomics methods, Heart Failure metabolism, Heart Failure drug therapy
- Abstract
Background: Altered metabolism plays a role in the pathophysiology of cardiac diseases, such as atrial fibrillation (AF) and heart failure (HF). We aimed to identify novel plasma metabolites and proteins associating with cardiac disease., Methods: Mendelian randomisation (MR) was used to assess the association of 174 metabolites measured in up to 86,507 participants with AF, HF, dilated cardiomyopathy (DCM), and non-ischemic cardiomyopathy (NICM). Subsequently, we sourced data on 1567 plasma proteins and performed cis MR to identify proteins affecting the identified metabolites as well as the cardiac diseases. Proteins were prioritised on cardiac expression and druggability, and mapped to biological pathways., Results: We identified 35 metabolites associating with cardiac disease. AF was affected by seventeen metabolites, HF by nineteen, DCM by four, and NCIM by taurine. HF was particularly enriched for phosphatidylcholines (p = 0.029) and DCM for acylcarnitines (p = 0.001). Metabolite involvement with AF was more uniform, spanning for example phosphatidylcholines, amino acids, and acylcarnitines. We identified 38 druggable proteins expressed in cardiac tissue, with a directionally concordant effect on metabolites and cardiac disease. We recapitulated known associations, for example between the drug target of digoxin (AT1B2), taurine and NICM risk. Additionally, we identified numerous novel findings, such as higher RET values associating with phosphatidylcholines and decreasing AF and HF. RET is targeted by drugs such as regorafenib which has known cardiotoxic side-effects. Pathway analysis implicated involvement of GDF15 signalling through RET, and ghrelin regulation of energy homeostasis in cardiac pathogenesis., Conclusions: This study identified 35 plasma metabolites involved with cardiac diseases and linked these to 38 druggable proteins, providing actionable leads for drug development., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
22. Prospective Association of the Mediterranean Diet with the Onset of Cardiometabolic Multimorbidity in a UK-Based Cohort: The EPIC-Norfolk Study.
- Author
-
Wang Q, Schmidt AF, and Wannamethee SG
- Abstract
Background: Cardiometabolic multimorbidity (CMM), defined as the co-occurrence of 2 or more cardiometabolic diseases, including myocardial infarction (MI), stroke, and type 2 diabetes (T2D), is an increasing public health challenge. Although poor diet is a known risk factor for a first cardiometabolic disease (FCMD), the relationship with subsequent occurrence of CMM is less studied., Objectives: This study aims to investigate the prospective association between baseline adherence to the Mediterranean diet and the onset of CMM across various follow-up durations., Methods: We used data from the European Prospective Investigation into Cancer-Norfolk cohort study of 21,900 adults, aged 40-79 free of prevalent MI, stroke, and T2D at baseline (1993-1997). A median-based Mediterranean diet score and a pyramid-based MDS (pyr-MDS) were used to measure baseline adherence to the Mediterranean diet. Multistate modeling was employed to investigate associations with the FCMD and the subsequent CMM event., Results: Over the entire follow-up period of 21.4 y (median), we observed 5028 FCMD and 734 CMM events. Multistate analysis indicated that the association between baseline Mediterranean diet and the risk of CMM may be stronger in shorter follow-up durations. Particularly, baseline pyr-MDS was significantly associated with the risk of subsequent CMM transitioning from FCMD when follow-up durations were limited to 10 and 15 y, with hazard ratio (95% confidence interval) being 0.67 (0.53, 0.84) and 0.80 (0.70, 0.92) per SD increase in pyr-MDS, respectively. Additionally, we observed that the risk of CMM transitioning from FCMD was modified by social class across shorter to longer follow-ups, where the impact of baseline Mediterranean diet was only significant in nonmanual workers., Conclusions: Baseline adherence to the Mediterranean diet was potentially associated with a lower risk of CMM transitioning from FCMD, particularly during shorter follow-up periods., Competing Interests: Conflict of interest The authors report no conflicts of interest., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis.
- Author
-
Schmidt AF, Davidson MH, Ditmarsch M, Kastelein JJ, and Finan C
- Subjects
- Humans, Cholesterol, HDL blood, Cardiovascular Diseases genetics, Cardiovascular Diseases blood, Cholesterol Ester Transfer Proteins genetics, Cholesterol Ester Transfer Proteins blood, Mendelian Randomization Analysis, Dementia blood, Dementia genetics, Dementia epidemiology
- Abstract
Background: Elevated concentrations of low-density lipoprotein cholesterol (LDL-C) are linked to dementia risk, and conversely, increased plasma concentrations of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein-A1 (Apo-A1) associate with decreased dementia risk. Inhibition of cholesteryl ester transfer protein (CETP) meaningfully affects the concentrations of these blood lipids and may therefore provide an opportunity to treat dementia., Methods: Drug target Mendelian randomization (MR) was employed to anticipate the on-target effects of lower CETP concentration (μg/mL) on plasma lipids, cardiovascular disease outcomes, autopsy confirmed Lewy body dementia (LBD), as well as Parkinson's dementia., Results: MR analysis of lower CETP concentration recapitulated the blood lipid effects observed in clinical trials of CETP-inhibitors, as well as protective effects on coronary heart disease (odds ratio (OR) 0.92, 95% confidence interval (CI) 0.89; 0.96), heart failure, abdominal aortic aneurysm, any stroke, ischemic stroke, and small vessel stroke (0.90, 95%CI 0.85; 0.96). Consideration of dementia related traits indicated that lower CETP concentrations were associated higher total brain volume (0.04 per standard deviation, 95%CI 0.02; 0.06), lower risk of LBD (OR 0.81, 95%CI 0.74; 0.89) and Parkinson's dementia risk (OR 0.26, 95%CI 0.14; 0.48). APOE4 stratified analyses suggested the LBD effect was most pronounced in APOE-ε4 + participants (OR 0.61 95%CI 0.51; 0.73), compared to APOE-ε4- (OR 0.89 95%CI 0.79; 1.01); interaction p-value 5.81 × 10
- 4 ., Conclusions: These results suggest that inhibition of CETP may be a viable strategy to treat dementia, with a more pronounced effect expected in APOE-ε4 carriers., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
24. Disease coverage of human genome-wide association studies and pharmaceutical research and development.
- Author
-
Gordillo-Marañón M, Schmidt AF, Warwick A, Tomlinson C, Ytsma C, Engmann J, Torralbo A, Maclean R, Sofat R, Langenberg C, Shah AD, Denaxas S, Pirmohamed M, Hemingway H, Hingorani AD, and Finan C
- Abstract
Background: Despite the growing interest in the use of human genomic data for drug target identification and validation, the extent to which the spectrum of human disease has been addressed by genome-wide association studies (GWAS), or by drug development, and the degree to which these efforts overlap remain unclear., Methods: In this study we harmonize and integrate different data sources to create a sample space of all the human drug targets and diseases and identify points of convergence or divergence of GWAS and drug development efforts., Results: We show that only 612 of 11,158 diseases listed in Human Disease Ontology have an approved drug treatment in at least one region of the world. Of the 1414 diseases that are the subject of preclinical or clinical phase drug development, only 666 have been investigated in GWAS. Conversely, of the 1914 human diseases that have been the subject of GWAS, 1121 have yet to be investigated in drug development., Conclusions: We produce target-disease indication lists to help the pharmaceutical industry to prioritize future drug development efforts based on genetic evidence, academia to prioritize future GWAS for diseases without effective treatments, and both sectors to harness genetic evidence to expand the indications for licensed drugs or to identify repurposing opportunities for clinical candidates that failed in their originally intended indication., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
25. Extracellular Vesicle ASC: A Novel Mediator for Lung-Brain Axis in Preterm Brain Injury.
- Author
-
Starke N, Challa NVD, Yuan H, Chen S, Duncan MR, Cabrera Ranaldi EDLRM, de Rivero Vaccari JP, Schott A, Aguilar AC, Lee YS, Khan A, Duara J, Tan A, Benny M, Schmidt AF, Young K, Bancalari E, Claure N, and Wu S
- Subjects
- Animals, Humans, Infant, Newborn, Mice, Bronchopulmonary Dysplasia metabolism, Bronchopulmonary Dysplasia pathology, Lung metabolism, Lung pathology, Infant, Premature, Female, Macrophages, Alveolar metabolism, Male, Brain metabolism, Brain pathology, Animals, Newborn, Blood-Brain Barrier metabolism, Blood-Brain Barrier pathology, Mice, Inbred C57BL, Extracellular Vesicles metabolism, Brain Injuries metabolism, Brain Injuries pathology, CARD Signaling Adaptor Proteins metabolism
- Abstract
Bronchopulmonary dysplasia (BPD) and neurodevelopmental impairment are among the most common morbidities affecting preterm infants. Although BPD is a predictor of poor neurodevelopmental outcomes, it is currently uncertain how BPD contributes to brain injury in preterm infants. Extracellular vesicles (EVs) are involved in interorgan communication in diverse pathological processes. ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain) is pivotal in inflammasome assembly and activation of inflammatory response. We assessed expression profiles of the alveolar macrophage (AM) markers CD11b, CD11c, and CD206 as well as ASC in EVs isolated from the plasma of preterm infants at risk for BPD at 1 week of age. We found that infants on higher fraction of inspired oxygen therapy (HO
2 ⩾30%) had increased concentrations of AM-derived EV-ASC compared with infants on lower fraction of inspired oxygen (LO2 <30%). To assess the function of these EVs, we performed adoptive transfer experiments by injecting them into the circulation of newborn mice. We discovered that mice that received EVs from infants on HO2 had increased lung inflammation, decreased alveolarization, and disrupted vascular development, the hallmarks of BPD. Importantly, these EVs crossed the blood-brain barrier, and the EVs from infants on HO2 caused inflammation, reduced cell survival, and increased cell death, with features of pyroptosis and necroptosis in the hippocampus. These results highlight a novel role for AM-derived EV-ASC in mediating the lung-to-brain cross-talk that is critical in the pathogenesis of BPD and brain injury and identify potential novel targets for preventing and treating BPD and brain injury in preterm infants.- Published
- 2024
- Full Text
- View/download PDF
26. Mediation analyses of longitudinal data investigating temporal associations between inflated sense of responsibility, obsessive-compulsive symptoms, and anger suppression.
- Author
-
Müller CL, Jelinek L, Schmidt AF, Mannsfeld AK, Miegel F, and Cludius B
- Subjects
- Humans, Female, Male, Adult, Longitudinal Studies, Mediation Analysis, Social Responsibility, Young Adult, Metacognition physiology, Middle Aged, Anger physiology, Obsessive-Compulsive Disorder psychology
- Abstract
Objective: Cognitive theories emphasize the central role of anger and anger suppression in obsessive-compulsive disorder (OCD). According to these theories, anger suppression is seen as a consequence of OCD, whereas cognitive beliefs, such as an inflated sense of responsibility, are seen as antecedent factors. To extend the findings from cross-sectional studies, the current study investigated the temporal associations between OCD symptoms, an inflated sense of responsibility, and anger suppression. Consistent with cognitive considerations, we hypothesized that OCD symptoms mediate the association between feelings of responsibility and anger suppression. These associations were also explored in patients presenting particularly high checking-related symptoms. Further, the stability of effects beyond controlling for depressive symptoms and medication intake was explored., Methods: A total of N = 48 patients with OCD (50% female, M = 32.46 [SD = 10.63] years of age) completed measures on obsessive beliefs, OCD symptoms, and anger suppression at three assessment points: before and after a metacognitive intervention as well as at a follow-up 6 months later. Mediation models investigating symptom associations at these three timepoints were conducted. Exploratory analyses investigating these associations in individuals presenting high checking-related symptoms (n = 20) and testing the stability of effects beyond controlling for depressive symptoms and medication intake were conducted., Results: The sense of responsibility did not significantly predict the level of anger suppression. A temporal association between OCD symptoms (as assessed with the self-report measure) and anger suppression could be evidenced, which was stable beyond controlling for depressive symptoms and medication intake. Against the expectations based on cognitive theories, the sense of responsibility did not predict OCD symptoms. No mediating effect of OCD symptoms was found., Conclusion: In line with cognitive viewpoints, the present study shows that higher OCD symptoms predict higher levels of anger suppression in a longitudinal design, thereby contributing to the suppression of anger. This effect seems to be independent from depressive symptoms and medication intake. The effect of sense of responsibility on OCD symptoms was less clear and could only be found in the subgroup of patients with OCD and checking-related symptoms, who generally presented higher levels of responsibility. Overall, this is the first study demonstrating temporal associations between OCD symptoms and anger suppression. Acknowledging that anger and anger suppression may be a consequence of OCD symptoms and may also affect aspects of psychotherapy, which can ultimately inform future adjustments to psychotherapeutic treatment., (© 2024 The Author(s). Journal of Clinical Psychology published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
27. Validation of machine learning-based risk stratification scores for patients with acute coronary syndrome treated with percutaneous coronary intervention.
- Author
-
Molenaar MA, Selder JL, Schmidt AF, Asselbergs FW, Nieuwendijk JD, van Dalfsen B, Schuuring MJ, Bouma BJ, Chamuleau SAJ, and Verouden NJ
- Abstract
Aims: This study aimed to validate the machine learning-based Global Registry of Acute Coronary Events (GRACE) 3.0 score and PRAISE (Prediction of Adverse Events following an Acute Coronary Syndrome) in patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) for predicting mortality., Methods and Results: Data of consecutive patients with ACS treated with PCI in a tertiary centre in the Netherlands between 2014 and 2021 were used for external validation. The GRACE 3.0 score for predicting in-hospital mortality was evaluated in 2759 patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) treated with PCI. The PRAISE score for predicting one-year mortality was evaluated in 4347 patients with ACS treated with PCI. Both risk scores were compared with the GRACE 2.0 score. The GRACE 3.0 score showed excellent discrimination [c-statistic 0.90 (95% CI 0.84, 0.94)] for predicting in-hospital mortality, with well-calibrated predictions (calibration-in-the large [CIL] -0.19 [95% CI -0.45, 0.07]). The PRAISE score demonstrated moderate discrimination [c-statistic 0.75 (95% CI 0.70, 0.80)] and overestimated the one-year risk of mortality [CIL -0.56 (95% CI -0.73, -0.39)]. Decision curve analysis demonstrated that the GRACE 3.0 score offered improved risk prediction compared with the GRACE 2.0 score, while the PRAISE score did not., Conclusion: This study in ACS patients treated with PCI provides suggestive evidence that the GRACE 3.0 score effectively predicts in-hospital mortality beyond the GRACE 2.0 score. The PRAISE score demonstrated limited potential for predicting one-year mortality risk. Further external validation studies in larger cohorts including patients without PCI are warranted., Competing Interests: Conflict of interest: AFS has received funding from New Amsterdam Pharma for unrelated projects. FWA is supported by UCL Hospitals NIHR Biomedical Research Centre, EU Horizon (AI4HF 101080430 and DataTools4Heart 101057849), Dutch Research Council (MyDigiTwin 628.011.213)., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
28. The Propensity for Deviant Sexual Behavior in the General Population: An Empirical Examination of the Motivation-Facilitation Model.
- Author
-
Lehmann RJB, Obermeier F, Schmidt AF, and Enge S
- Abstract
In their influential paper Wurtele et al. (2014) investigated the degree to which individuals within the general population ( N = 435) express sexual interest in children. In the male population of their study ( n = 173), about 6% showed a propensity to engage in sexual activity with a child. Based on a German general population sample consisting of women and men ( N = 911, n = 206 males), we were able to replicate most of the results of Wurtele and colleagues (e.g., 6% of men indicated some likelihood of having sex with a child). To explain sexual offending, Seto (2019) developed the motivation-facilitation model (MFM). In our study, we were interested whether this model also translates to explaining the propensity for deviant sexual behavior in the general population. Moderated hierarchical logistic regression analyses revealed that hypersexuality and sexual fantasies had significant effects as motivating factors for deviant sexual behavior (e.g., sexually assaulting an adult), whereas we found no significant effect of psychopathy as a facilitator. For the prediction of child sexual abuse , only hypersexuality had a significant effect. Notably, after including gender in both models the effect of hypersexuality was no longer significant. Accordingly, we were able to show that the MFM is useful in explaining the propensity for deviant sexual behavior foremost in the male general population. Thus, in clinical practice an assessment of hypersexuality seems to be most relevant for the male population., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
29. Public Stigmatizing Reactions Toward Nonoffending Pedophilic Individuals Seeking to Relieve Sexual Arousal.
- Author
-
Lehmann RJB, Jahnke S, Bartels R, Butzek J, Molitor A, and Schmidt AF
- Subjects
- Humans, Male, Female, Adult, Young Adult, Middle Aged, Social Stigma, Stereotyping, Sexual Behavior psychology, Adolescent, Pedophilia psychology, Sexual Arousal
- Abstract
People with pedophilia (PWP) can deal with their sexual desires by relieving sexual arousal without sexually exploiting children. Study 1 investigated whether public reactions toward nonoffending pedophilic men are affected by their strategies to relieve sexual arousal (nonsexual pictures vs. child sex dolls) or to reduce their sex drive via testosterone lowering medication in legally nonproblematic ways. A sample of German-speaking participants ( N = 143) read three vignettes describing PWP using either of these strategies. Participants' (59.4% females) mean age was 39.7 ( SD = 15.6). Although no significant difference was detected between the nonsexual pictures and sex dolls conditions on cognitive (except for dangerousness), affective, and behavioral levels, both consistently elicited more stigmatizing reactions than the testosterone-lowering medication condition. To investigate if this effect was driven by disapproving any relief of sexual arousal or the use of actual child stimuli in particular, Study 2 ( N = 151) added two conditions with PWP using adult child-like stimuli to relieve sexual arousal: adult-as-schoolgirl porn and adult partner with childlike appearance. Here, Participants' (57.6% females) mean age was 28.0 ( SD = 13.3). Results indicate that stigmatization was driven by disapproving the use of child stimuli rather than the relief of sexual arousal in general. Individuals with a sexual interest in children face strong stigmatizing reactions, which are only alleviated when they are described as undergoing treatment lowering sex drive or - to a lesser extent - being able to mate with an adult partner or using porn with adult actors posing as schoolgirls.
- Published
- 2024
- Full Text
- View/download PDF
30. IC100, a humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice.
- Author
-
Yuan H, Chen S, Duncan MR, de Rivero Vaccari JP, Keane RW, Dalton Dietrich W, Chou TH, Benny M, Schmidt AF, Young K, Park KK, Porciatti V, Elizabeth Hartnett M, and Wu S
- Subjects
- Animals, Mice, Antibodies, Monoclonal, Humanized pharmacology, Mice, Inbred C57BL, Animals, Newborn, Disease Models, Animal, Humans, Hyperoxia pathology, Hyperoxia complications, Retina pathology, Retina metabolism, Retina drug effects, CARD Signaling Adaptor Proteins metabolism, Mice, Transgenic, Retinal Neovascularization pathology, Retinal Neovascularization metabolism, Retinal Neovascularization drug therapy, Microglia pathology, Microglia metabolism, Microglia drug effects, Oxygen, Retinopathy of Prematurity pathology, Retinopathy of Prematurity drug therapy, Retinopathy of Prematurity metabolism
- Abstract
Background: Retinopathy of prematurity (ROP), which often presents with bronchopulmonary dysplasia (BPD), is among the most common morbidities affecting extremely premature infants and is a leading cause of severe vision impairment in children worldwide. Activations of the inflammasome cascade and microglia have been implicated in playing a role in the development of both ROP and BPD. Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) is pivotal in inflammasome assembly. Utilizing mouse models of both oxygen-induced retinopathy (OIR) and BPD, this study was designed to test the hypothesis that hyperoxia induces ASC speck formation, which leads to microglial activation and retinopathy, and that inhibition of ASC speck formation by a humanized monoclonal antibody, IC100, directed against ASC, will ameliorate microglial activation and abnormal retinal vascular formation., Methods: We first tested ASC speck formation in the retina of ASC-citrine reporter mice expressing ASC fusion protein with a C-terminal citrine (fluorescent GFP isoform) using a BPD model that causes both lung and eye injury by exposing newborn mice to room air (RA) or 85% O
2 from postnatal day (P) 1 to P14. The retinas were dissected on P14 and retinal flat mounts were used to detect vascular endothelium with AF-594-conjugated isolectin B4 (IB4) and citrine-tagged ASC specks. To assess the effects of IC100 on an OIR model, newborn ASC citrine reporter mice and wildtype mice (C57BL/6 J) were exposed to RA from P1 to P6, then 75% O2 from P7 to P11, and then to RA from P12 to P18. At P12 mice were randomized to the following groups: RA with placebo PBS (RA-PBS), O2 with PBS (O2 -PBS), O2 + IC100 intravitreal injection (O2 -IC100-IVT), and O2 + IC100 intraperitoneal injection (O2 -IC100-IP). Retinal vascularization was evaluated by flat mount staining with IB4. Microglial activation was detected by immunofluorescence staining for allograft inflammatory factor 1 (AIF-1) and CD206. Retinal structure was analyzed on H&E-stained sections, and function was analyzed by pattern electroretinography (PERG). RNA-sequencing (RNA-seq) of the retinas was performed to determine the transcriptional effects of IC100 treatment in OIR., Results: ASC specks were significantly increased in the retinas by hyperoxia exposure and colocalized with the abnormal vasculature in both BPD and OIR models, and this was associated with increased microglial activation. Treatment with IC100-IVT or IC100-IP significantly reduced vaso-obliteration and intravitreal neovascularization. IC100-IVT treatment also reduced retinal microglial activation, restored retinal structure, and improved retinal function. RNA-seq showed that IC100 treatment corrected the induction of genes associated with angiogenesis, leukocyte migration, and VEGF signaling caused by O2 . IC100 also corrected the suppression of genes associated with cell junction assembly, neuron projection, and neuron recognition caused by O2 ., Conclusion: These data demonstrate the crucial role of ASC in the pathogenesis of OIR and the efficacy of a humanized therapeutic anti-ASC antibody in treating OIR mice. Thus, this anti-ASC antibody may potentially be considered in diseases associated with oxygen stresses and retinopathy, such as ROP., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
31. Neonatal hyperoxia exposure leads to developmental programming of cardiovascular and renal disease in adult rats.
- Author
-
DeFreitas MJ, Shelton EL, Schmidt AF, Ballengee S, Tian R, Chen P, Sharma M, Levine A, Katz ED, Rojas C, Abitbol CL, Hunter J, Kulandavelu S, Wu S, Young KC, and Benny M
- Subjects
- Animals, Rats, Cardiovascular Diseases etiology, Cardiovascular Diseases metabolism, Cardiovascular Diseases pathology, Kidney metabolism, Kidney pathology, Fibrosis, Vascular Stiffness, Male, Female, Rats, Sprague-Dawley, Aorta pathology, Aorta metabolism, Hyperoxia metabolism, Animals, Newborn, Kidney Diseases etiology, Kidney Diseases pathology, Kidney Diseases metabolism
- Abstract
Premature infants are often exposed to hyperoxia. However, there is limited data regarding the mechanistic underpinnings linking neonatal hyperoxia exposure and its contribution to cardio-renal dysfunction in adults born preterm. Our objective was to determine whether neonatal hyperoxia induces systemic vascular stiffness and cardio-renal dysfunction in adulthood. Newborn rats were randomly assigned to room air (RA) or hyperoxia (85% O
2 ) from postnatal day 1 to 14, then recovered in RA until 1 year of life. Arterial stiffness, cardio-renal histomorphometry, and fibrosis in the aorta, heart, and kidney were assessed. RNA-sequencing (RNA-seq) of the aorta and kidney was also done. Adult rats exposed to neonatal hyperoxia had increased aortic and mesenteric artery stiffness as demonstrated by wire and pressure myography. They also had cardiomyocyte hypertrophy, glomerulomegaly, and tubular injury. Hyperoxia exposure altered the transcriptome profile associated with fibrosis and matrix remodeling in the aorta and kidney. There was also increased TGF-β1 levels and fibrosis in the aorta, left ventricle, and kidney. In conclusion, neonatal hyperoxia exposure was associated with systemic vascular and cardio-renal alterations in 1-year-old rats. Further studies to determine how targeted therapies could reprogram cardio-renal injury after neonatal hyperoxia exposure are indicated., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
32. Why do users continue to contribute to darknet Child Sexual Abuse Material forums? Examining social exchange, social capital, and social learning explanations using digital forensic artifacts.
- Author
-
Blokland A, Daser A, de Boer M, Gannon C, Gnielka F, Huikuri S, Reichel R, Shäfer T, Schmidt AF, Staciwa K, and Lehmann R
- Subjects
- Humans, Child, Social Network Analysis, Social Networking, Social Media statistics & numerical data, Female, Male, Law Enforcement methods, Child Abuse, Sexual psychology, Child Abuse, Sexual statistics & numerical data, Social Learning, Social Capital
- Abstract
Background: The darknet hosts an increasing number of hidden services dedicated to the distribution of child sexual abuse material (CSAM). Given that by contributing CSAM to the forum members subject themselves to criminal prosecution, questions regarding the motivation for members contributing to darknet CSAM forums arise., Objective: Building on insights gained from research into clearnet communities, here we examine the extent to which social incentives generated by the online CSAM community may explain members' posting behavior on darknet CSAM forums., Participants and Setting: We analyze digital forensic artifacts on the online behavior of members of a darknet CSAM forum that was shut down by law enforcement agencies in July 2015., Methods: We apply group-based trajectory modelling (GBTM), social network analysis, and mixed-effect survival models., Results: Applying GBTM three posting trajectories can be distinguished. Social network analyses finds the reply network to be more centralized than predicted by chance. Mixed-effect survival models show positive associations between the length of members' first post and the time since members' first registration on the forum and subsequent posting. Contrarily, the number of replies received appears to mitigate subsequent posting., Conclusions: Findings show posting activity on the forum to be concentrated in a minority of forum members who show posting trajectories that are both frequent and persistent. Results further suggest persistence in posting is motivated by social identity and, to a lesser extent, differential association processes., Competing Interests: Declaration of competing interest The authors report there are no competing interests to declare., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
33. Genetic evidence for serum amyloid P component as a drug target in neurodegenerative disorders.
- Author
-
Schmidt AF, Finan C, Chopade S, Ellmerich S, Rossor MN, Hingorani AD, and Pepys MB
- Subjects
- Humans, Alzheimer Disease genetics, Alzheimer Disease metabolism, Alzheimer Disease etiology, Polymorphism, Single Nucleotide, Genetic Predisposition to Disease, Mendelian Randomization Analysis, Biomarkers, tau Proteins metabolism, tau Proteins genetics, Lewy Body Disease genetics, Lewy Body Disease metabolism, Male, Female, Genome-Wide Association Study, Neurodegenerative Diseases genetics, Neurodegenerative Diseases etiology, Neurodegenerative Diseases metabolism, Serum Amyloid P-Component metabolism, Serum Amyloid P-Component genetics
- Abstract
The mechanisms responsible for neuronal death causing cognitive loss in Alzheimer's disease (AD) and many other dementias are not known. Serum amyloid P component (SAP) is a constitutive plasma protein, which is cytotoxic for cerebral neurones and also promotes formation and persistence of cerebral A β amyloid and neurofibrillary tangles. Circulating SAP, which is produced exclusively by the liver, is normally almost completely excluded from the brain. Conditions increasing brain exposure to SAP increase dementia risk, consistent with a causative role in neurodegeneration. Furthermore, neocortex content of SAP is strongly and independently associated with dementia at death. Here, seeking genomic evidence for a causal link of SAP with neurodegeneration, we meta-analysed three genome-wide association studies of 44 288 participants, then conducted cis -Mendelian randomization assessment of associations with neurodegenerative diseases. Higher genetically instrumented plasma SAP concentrations were associated with AD (odds ratio 1.07, 95% confidence interval (CI) 1.02; 1.11, p = 1.8 × 10
-3 ), Lewy body dementia (odds ratio 1.37, 95%CI 1.19; 1.59, p = 1.5 × 10-5 ) and plasma tau concentration (0.06 log2 (ng l-1 ) 95%CI 0.03; 0.08, p = 4.55 × 10-6 ). These genetic findings are consistent with neuropathogenicity of SAP. Depletion of SAP from the blood and the brain, by the safe, well tolerated, experimental drug miridesap may thus be neuroprotective.- Published
- 2024
- Full Text
- View/download PDF
34. NMR metabolomic modeling of age and lifespan: A multicohort analysis.
- Author
-
Lau CE, Manou M, Markozannes G, Ala-Korpela M, Ben-Shlomo Y, Chaturvedi N, Engmann J, Gentry-Maharaj A, Herzig KH, Hingorani A, Järvelin MR, Kähönen M, Kivimäki M, Lehtimäki T, Marttila S, Menon U, Munroe PB, Palaniswamy S, Providencia R, Raitakari O, Schmidt AF, Sebert S, Wong A, Vineis P, Tzoulaki I, and Robinson O
- Subjects
- Humans, Aged, Middle Aged, Aged, 80 and over, Adult, Male, Female, Longevity, Cohort Studies, Young Adult, Risk Factors, Finland epidemiology, Metabolomics methods, Aging, Magnetic Resonance Spectroscopy methods
- Abstract
Metabolomic age models have been proposed for the study of biological aging, however, they have not been widely validated. We aimed to assess the performance of newly developed and existing nuclear magnetic resonance spectroscopy (NMR) metabolomic age models for prediction of chronological age (CA), mortality, and age-related disease. Ninety-eight metabolic variables were measured in blood from nine UK and Finnish cohort studies (N ≈31,000 individuals, age range 24-86 years). We used nonlinear and penalized regression to model CA and time to all-cause mortality. We examined associations of four new and two previously published metabolomic age models, with aging risk factors and phenotypes. Within the UK Biobank (N ≈102,000), we tested prediction of CA, incident disease (cardiovascular disease (CVD), type-2 diabetes mellitus, cancer, dementia, and chronic obstructive pulmonary disease), and all-cause mortality. Seven-fold cross-validated Pearson's r between metabolomic age models and CA ranged between 0.47 and 0.65 in the training cohort set (mean absolute error: 8-9 years). Metabolomic age models, adjusted for CA, were associated with C-reactive protein, and inversely associated with glomerular filtration rate. Positively associated risk factors included obesity, diabetes, smoking, and physical inactivity. In UK Biobank, correlations of metabolomic age with CA were modest (r = 0.29-0.33), yet all metabolomic model scores predicted mortality (hazard ratios of 1.01 to 1.06/metabolomic age year) and CVD, after adjustment for CA. While metabolomic age models were only moderately associated with CA in an independent population, they provided additional prediction of morbidity and mortality over CA itself, suggesting their wider applicability., (© 2024 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
35. Comparing the effects of CETP in East Asian and European ancestries: a Mendelian randomization study.
- Author
-
Dunca D, Chopade S, Gordillo-Marañón M, Hingorani AD, Kuchenbaecker K, Finan C, and Schmidt AF
- Subjects
- Female, Humans, Male, Middle Aged, Anticholesteremic Agents therapeutic use, Blood Pressure genetics, Blood Pressure drug effects, Cardiovascular Diseases genetics, Cholesterol, HDL blood, Coronary Disease genetics, Coronary Disease blood, East Asian People genetics, Polymorphism, Single Nucleotide, White People genetics, Cholesterol Ester Transfer Proteins genetics, Cholesterol, LDL blood, Mendelian Randomization Analysis
- Abstract
CETP inhibitors are a class of lipid-lowering drugs in development for treatment of coronary heart disease (CHD). Genetic studies in East Asian ancestry have interpreted the lack of CETP signal with low-density lipoprotein cholesterol (LDL-C) and lack of drug target Mendelian randomization (MR) effect on CHD as evidence that CETP inhibitors might not be effective in East Asian participants. Capitalizing on recent increases in sample size of East Asian genetic studies, we conducted a drug target MR analysis, scaled to a standard deviation increase in high-density lipoprotein cholesterol. Despite finding evidence for possible neutral effects of lower CETP levels on LDL-C, systolic blood pressure and pulse pressure in East Asians (interaction p-values < 1.6 × 10
-3 ), effects on cardiovascular outcomes were similarly protective in both ancestry groups. In conclusion, on-target inhibition of CETP is anticipated to decrease cardiovascular disease in individuals of both European and East Asian ancestries., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
36. Association of Life's Simple 7 lifestyle metric with cardiometabolic disease-free life expectancy in older British men.
- Author
-
Wang Q, Schmidt AF, Lennon LT, Papacosta O, Whincup PH, and Wannamethee G
- Abstract
Background: Cardiometabolic diseases (CMD), including myocardial infarction, stroke, and type 2 diabetes, are leading causes of disability and mortality globally, particularly for people at an older age. The impact of adhering to the Life's Simple 7 (LS7) on the number of years an individual will live without CMD in older adults remains less studied., Methods: This study included a cohort of 2662 British men aged 60-79 years free of CMD at baseline from the British Regional Heart Study (BRHS). Each LS7 factor (BMI, blood pressure, blood glucose, total cholesterol, smoking, physical activity, and diet) was categorized as poor, intermediate, or ideal, and a composite LS7 adherence was determined by summing the number of LS7 ideal levels achieved. Flexible parametric Royston-Parmar proportional-hazards model was applied to estimate CMD-free life expectancy., Results: Here we show that compared to men with the lowest LS7 adherence [with 18.42 years (95% CI: 16.93, 19.90) of CMD-free life at age 60], men having an ideal LS7 adherence are estimated to gain an additional 4.37 years (95% CI: 2.95, 5.79) of CMD-free life. The CMD-free life gain benefits are consistent across social class groups of manual and non-manual workers. Among LS7 factors, achieving an ideal physical activity provides the largest CMD-free survival benefit: 4.84 years (95% CI: 3.37, 6.32) of additional CMD-free life compared with the physically inactive group., Conclusions: Our study quantifies and highlights the benefits of adhering to the LS7 ideal levels for living a longer life without CMD in older adults., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
37. A Dress Is Not a Yes: Towards an Indirect Mouse-Tracking Measure of Men's Overreliance on Global Cues in the Context of Sexual Flirting.
- Author
-
Landwehr I, Mundloch K, and Schmidt AF
- Subjects
- Humans, Male, Adult, Young Adult, Female, Sexual Arousal, Clothing psychology, Adolescent, Cues, Sexual Behavior psychology
- Abstract
Assessing another person's intention to flirt and, relatedly, their sexual interest is based on the interpretation and weighting of global (e.g., clothing style) and specific (e.g., facial expression) cues. Since cue incongruency increases the risk of erroneous judgments and thus can entail undesirable outcomes for both parties involved, detection of an individual propensity for overly relying on global (sexual) rather than specific (affective) cues is of social and clinical-forensic importance. Using a purpose-designed and pre-validated stimulus set, we developed a mouse-tracking task as an indirect behavioral measure for males' overreliance on global cues (OGC) in the context of sexual flirting. In a convenience sample of heterosexual cisgender men (N = 79), experimentally induced sexual arousal was shown to increase the probability of OGC as a function of task difficulty (i.e., congruent or incongruent combinations of global and specific cues displayed by a potential female flirting partner). While error rate and reaction time proved to be indicators of OGC, the spatial measures maximum deviation and area under the curve provided less consistent results. In addition, error rate suggested sex drive and sexual objectification to act as moderators of the relationship between sexual arousal and OGC. Exploratory analysis further revealed a theoretically meaningful pattern of correlations between mouse-tracking measures and self-report measures of problematic (e.g., disinhibited, exploitative) sexuality. Implications of the results are discussed and a framework for differentiating potential causes of OGC (i.e., misperception, lack of self-control, and egocentric hedonism) is proposed., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
38. Utilizing multimodal AI to improve genetic analyses of cardiovascular traits.
- Author
-
Zhou Y, Cosentino J, Yun T, Biradar MI, Shreibati J, Lai D, Schwantes-An TH, Luben R, McCaw Z, Engmann J, Providencia R, Schmidt AF, Munroe P, Yang H, Carroll A, Khawaja AP, McLean CY, Behsaz B, and Hormozdiari F
- Abstract
Electronic health records, biobanks, and wearable biosensors contain multiple high-dimensional clinical data (HDCD) modalities (e.g., ECG, Photoplethysmography (PPG), and MRI) for each individual. Access to multimodal HDCD provides a unique opportunity for genetic studies of complex traits because different modalities relevant to a single physiological system (e.g., circulatory system) encode complementary and overlapping information. We propose a novel multimodal deep learning method, M-REGLE, for discovering genetic associations from a joint representation of multiple complementary HDCD modalities. We showcase the effectiveness of this model by applying it to several cardiovascular modalities. M-REGLE jointly learns a lower representation (i.e., latent factors) of multimodal HDCD using a convolutional variational autoencoder, performs genome wide association studies (GWAS) on each latent factor, then combines the results to study the genetics of the underlying system. To validate the advantages of M-REGLE and multimodal learning, we apply it to common cardiovascular modalities (PPG and ECG), and compare its results to unimodal learning methods in which representations are learned from each data modality separately, but the downstream genetic analyses are performed on the combined unimodal representations. M-REGLE identifies 19.3% more loci on the 12-lead ECG dataset, 13.0% more loci on the ECG lead I + PPG dataset, and its genetic risk score significantly outperforms the unimodal risk score at predicting cardiac phenotypes, such as atrial fibrillation (Afib), in multiple biobanks.
- Published
- 2024
- Full Text
- View/download PDF
39. Pathogenesis and Physiologic Mechanisms of Neonatal Pulmonary Hypertension: Preclinical Studies.
- Author
-
Young KC, Schmidt AF, Tan AW, Sbragia L, Elsaie A, and Shivanna B
- Subjects
- Infant, Newborn, Humans, Lung, Vascular Resistance, Hypertension, Pulmonary, Bronchopulmonary Dysplasia, Hernias, Diaphragmatic, Congenital therapy
- Abstract
Neonatal pulmonary hypertension (PH) is a devastating disorder of the pulmonary vasculature characterized by elevated pulmonary vascular resistance and mean pulmonary arterial pressure. Occurring predominantly because of maldevelopment or maladaptation of the pulmonary vasculature, PH in neonates is associated with suboptimal short-term and long-term outcomes because its pathobiology is unclear in most circumstances, and it responds poorly to conventional pulmonary vasodilators. Understanding the pathogenesis and pathophysiology of neonatal PH can lead to novel strategies and precise therapies. The review is designed to achieve this goal by summarizing pulmonary vascular development and the pathogenesis and pathophysiology of PH associated with maladaptation, bronchopulmonary dysplasia, and congenital diaphragmatic hernia based on evidence predominantly from preclinical studies. We also discuss the pros and cons of and provide future directions for preclinical studies in neonatal PH., Competing Interests: Disclosure The authors have nothing to disclose., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. Prioritising genetic findings for drug target identification and validation.
- Author
-
Hukerikar N, Hingorani AD, Asselbergs FW, Finan C, and Schmidt AF
- Subjects
- Humans, Death-Associated Protein Kinases genetics, Proteins genetics, Genome-Wide Association Study, Non-alcoholic Fatty Liver Disease drug therapy, Non-alcoholic Fatty Liver Disease genetics, Non-alcoholic Fatty Liver Disease metabolism
- Abstract
The decreasing costs of high-throughput genetic sequencing and increasing abundance of sequenced genome data have paved the way for the use of genetic data in identifying and validating potential drug targets. However, the number of identified potential drug targets is often prohibitively large to experimentally evaluate in wet lab experiments, highlighting the need for systematic approaches for target prioritisation. In this review, we discuss principles of genetically guided drug development, specifically addressing loss-of-function analysis, colocalization and Mendelian randomisation (MR), and the contexts in which each may be most suitable. We subsequently present a range of biomedical resources which can be used to annotate and prioritise disease-associated proteins identified by these studies including 1) ontologies to map genes, proteins, and disease, 2) resources for determining the druggability of a potential target, 3) tissue and cell expression of the gene encoding the potential target, and 4) key biological pathways involving the potential target. We illustrate these concepts through a worked example, identifying a prioritised set of plasma proteins associated with non-alcoholic fatty liver disease (NAFLD). We identified five proteins with strong genetic support for involvement with NAFLD: CYB5A, NT5C, NCAN, TGFBI and DAPK2. All of the identified proteins were expressed in both liver and adipose tissues, with TGFBI and DAPK2 being potentially druggable. In conclusion, the current review provides an overview of genetic evidence for drug target identification, and how biomedical databases can be used to provide actionable prioritisation, fully informing downstream experimental validation., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AFS and CF have received funding from New Amsterdam Pharma for an unrelated project., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. c-Myc Drives inflammation of the maternal-fetal interface, and neonatal lung remodeling induced by intra-amniotic inflammation.
- Author
-
Tan AW, Tong X, Alvarez-Cubela S, Chen P, Santana AG, Morales AA, Tian R, Infante R, Nunes de Paiva V, Kulandavelu S, Benny M, Dominguez-Bendala J, Wu S, Young KC, Rodrigues CO, and Schmidt AF
- Abstract
Background: Intra-amniotic inflammation (IAI) is associated with increased risk of preterm birth and bronchopulmonary dysplasia (BPD), but the mechanisms by which IAI leads to preterm birth and BPD are poorly understood, and there are no effective therapies for preterm birth and BPD. The transcription factor c-Myc regulates various biological processes like cell growth, apoptosis, and inflammation. We hypothesized that c-Myc modulates inflammation at the maternal-fetal interface, and neonatal lung remodeling. The objectives of our study were 1) to determine the kinetics of c-Myc in the placenta, fetal membranes and neonatal lungs exposed to IAI, and 2) to determine the role of c-Myc in modulating inflammation at the maternal-fetal interface, and neonatal lung remodeling induced by IAI. Methods: Pregnant Sprague-Dawley rats were randomized into three groups: 1) Intra-amniotic saline injections only (control), 2) Intra-amniotic lipopolysaccharide (LPS) injections only, and 3) Intra-amniotic LPS injections with c-Myc inhibitor 10058-F4. c-Myc expression, markers of inflammation, angiogenesis, immunohistochemistry, and transcriptomic analyses were performed on placenta and fetal membranes, and neonatal lungs to determine kinetics of c-Myc expression in response to IAI, and effects of prenatal systemic c-Myc inhibition on lung remodeling at postnatal day 14. Results: c-Myc was upregulated in the placenta, fetal membranes, and neonatal lungs exposed to IAI. IAI caused neutrophil infiltration and neutrophil extracellular trap (NET) formation in the placenta and fetal membranes, and neonatal lung remodeling with pulmonary hypertension consistent with a BPD phenotype. Prenatal inhibition of c-Myc with 10058-F4 in IAI decreased neutrophil infiltration and NET formation, and improved neonatal lung remodeling induced by LPS, with improved alveolarization, increased angiogenesis, and decreased pulmonary vascular remodeling. Discussion: In a rat model of IAI, c-Myc regulates neutrophil recruitment and NET formation in the placenta and fetal membranes. c-Myc also participates in neonatal lung remodeling induced by IAI. Further studies are needed to investigate c-Myc as a potential therapeutic target for IAI and IAI-associated BPD., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Tan, Tong, Alvarez-Cubela, Chen, Santana, Morales, Tian, Infante, Nunes de Paiva, Kulandavelu, Benny, Dominguez-Bendala, Wu, Young, Rodrigues and Schmidt.)
- Published
- 2024
- Full Text
- View/download PDF
42. Chorioamnionitis accelerates granule cell and oligodendrocyte maturation in the cerebellum of preterm nonhuman primates.
- Author
-
Newman J, Tong X, Tan A, Yeasky T, De Paiva VN, Presicce P, Kannan PS, Williams K, Damianos A, Tamase Newsam M, Benny MK, Wu S, Young KC, Miller LA, Kallapur SG, Chougnet CA, Jobe AH, Brambilla R, and Schmidt AF
- Subjects
- Infant, Newborn, Female, Infant, Animals, Humans, Pregnancy, Hedgehog Proteins, Macaca mulatta, Escherichia coli, Infant, Premature, Cerebellum, RNA, Small Nuclear, Chorioamnionitis, Premature Birth
- Abstract
Background: Preterm birth is often associated with chorioamnionitis and leads to increased risk of neurodevelopmental disorders, such as autism. Preterm birth can lead to cerebellar underdevelopment, but the mechanisms of disrupted cerebellar development in preterm infants are not well understood. The cerebellum is consistently affected in people with autism spectrum disorders, showing reduction of Purkinje cells, decreased cerebellar grey matter, and altered connectivity., Methods: Preterm rhesus macaque fetuses were exposed to intra-amniotic LPS (1 mg, E. coli O55:B5) at 127 days (80%) gestation and delivered by c-section 5 days after injections. Maternal and fetal plasma were sampled for cytokine measurements. Chorio-decidua was analyzed for immune cell populations by flow cytometry. Fetal cerebellum was sampled for histology and molecular analysis by single-nuclei RNA-sequencing (snRNA-seq) on a 10× chromium platform. snRNA-seq data were analyzed for differences in cell populations, cell-type specific gene expression, and inferred cellular communications., Results: We leveraged snRNA-seq of the cerebellum in a clinically relevant rhesus macaque model of chorioamnionitis and preterm birth, to show that chorioamnionitis leads to Purkinje cell loss and disrupted maturation of granule cells and oligodendrocytes in the fetal cerebellum at late gestation. Purkinje cell loss is accompanied by decreased sonic hedgehog signaling from Purkinje cells to granule cells, which show an accelerated maturation, and to oligodendrocytes, which show accelerated maturation from pre-oligodendrocytes into myelinating oligodendrocytes., Conclusion: These findings suggest a role of chorioamnionitis on disrupted cerebellar maturation associated with preterm birth and on the pathogenesis of neurodevelopmental disorders among preterm infants., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
43. Penetrance and Prognosis of MYH7 Variant-Associated Cardiomyopathies: Results From a Dutch Multicenter Cohort Study.
- Author
-
Jansen M, de Brouwer R, Hassanzada F, Schoemaker AE, Schmidt AF, Kooijman-Reumerman MD, Bracun V, Slieker MG, Dooijes D, Vermeer AMC, Wilde AAM, Amin AS, Lekanne Deprez RH, Herkert JC, Christiaans I, de Boer RA, Jongbloed JDH, van Tintelen JP, Asselbergs FW, and Baas AF
- Subjects
- Humans, Male, Adult, Child, Preschool, Child, Female, Penetrance, Cohort Studies, Prognosis, Mutation, Myosin Heavy Chains genetics, Cardiac Myosins genetics, Heart Failure, Cardiomyopathies genetics, Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated genetics
- Abstract
Background: MYH7 variants cause hypertrophic cardiomyopathy (HCM), noncompaction cardiomyopathy (NCCM), and dilated cardiomyopathy (DCM). Screening of relatives of patients with genetic cardiomyopathy is recommended from 10 to 12 years of age onward, irrespective of the affected gene., Objectives: This study sought to study the penetrance and prognosis of MYH7 variant-associated cardiomyopathies., Methods: In this multicenter cohort study, penetrance and major cardiomyopathy-related events (MCEs) were assessed in carriers of (likely) pathogenic MYH7 variants by using Kaplan-Meier curves and log-rank tests. Prognostic factors were evaluated using Cox regression with time-dependent coefficients., Results: In total, 581 subjects (30.1% index patients, 48.4% male, median age 37.0 years [IQR: 19.5-50.2 years]) were included. HCM was diagnosed in 226 subjects, NCCM in 70, and DCM in 55. Early penetrance and MCEs (age <12 years) were common among NCCM-associated variant carriers (21.2% and 12.0%, respectively) and DCM-associated variant carriers (15.3% and 10.0%, respectively), compared with HCM-associated variant carriers (2.9% and 2.1%, respectively). Penetrance was significantly increased in carriers of converter region variants (adjusted HR: 1.87; 95% CI: 1.15-3.04; P = 0.012) and at age ≤1 year in NCCM-associated or DCM-associated variant carriers (adjusted HR: 21.17; 95% CI: 4.81-93.20; P < 0.001) and subjects with a family history of early MCEs (adjusted HR: 2.45; 95% CI: 1.09-5.50; P = 0.030). The risk of MCE was increased in subjects with a family history of early MCEs (adjusted HR: 1.82; 95% CI: 1.15-2.87; P = 0.010) and at age ≤5 years in NCCM-associated or DCM-associated variant carriers (adjusted HR: 38.82; 95% CI: 5.16-291.88; P < 0.001)., Conclusions: MYH7 variants can cause cardiomyopathies and MCEs at a young age. Screening at younger ages may be warranted, particularly in carriers of NCCM- or DCM-associated variants and/or with a family history of MCEs at <12 years., Competing Interests: Funding Support and Author Disclosures This work was supported by the Netherlands Cardiovascular Research Initiative with the support of the Dutch Heart Foundation. Dr Jansen has received support from the Netherlands Cardiovascular Research Initiative with the support of the Dutch Heart Foundation (CVON2014-40 DOSIS, DCVA [Dutch Cardiovascular Alliance] 2020B005 DoubleDose) and from the Dutch Heart Foundation (Dekker 2015T041). Dr Christiaans has received support from the Netherlands Cardiovascular Research Initiative with the support of the Dutch Heart Foundation (CVON2015-12 e-Detect). Dr de Boer has received support from the Netherlands Cardiovascular Research Initiative with the support of the Dutch Heart Foundation (CVON2014-40 DOSIS, DCVA 2020B005 DoubleDose). Dr van Tintelen has received support from the Netherlands Cardiovascular Research Initiative with the support of the Dutch Heart Foundation (CVON2014-40 DOSIS, DCVA 2020B005 DoubleDose and CVON2015-12 e-Detect). Dr Asselbergs has received support from the Netherlands Cardiovascular Research Initiative with the support of the Dutch Heart Foundation (CVON2014-40 DOSIS, DCVA 2020B005 DoubleDose and CVON2015-12 e-Detect) and from the UCL Hospitals NIHR Biomedical Research Centre. Dr Baas has received support from the Netherlands Cardiovascular Research Initiative with the support of the Dutch Heart Foundation (CVON2014-40 DOSIS, DCVA 2020B005 DoubleDose and CVON2015-12 e-Detect) and from the Dutch Heart Foundation (Dekker 2015T041). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Influence of stressful life events and personality traits on PLN cardiomyopathy severity: an exploratory study.
- Author
-
van Drie E, Taal SEL, Schmidt AF, Verstraelen TE, de Brouwer R, Schoormans D, Mommersteeg PMC, de Boer RA, Wilde AAM, Asselbergs FW, Baas AF, van Tintelen JP, and van den Heuvel LM
- Subjects
- Humans, Personality, Stress, Psychological complications, Cardiomyopathies complications
- Abstract
Competing Interests: Conflict of interest: none declared.
- Published
- 2023
- Full Text
- View/download PDF
45. Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity: an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers.
- Author
-
Jansen M, Schmidt AF, Jans JJM, Christiaans I, van der Crabben SN, Hoedemaekers YM, Dooijes D, Jongbloed JDH, Boven LG, Lekanne Deprez RH, Wilde AAM, van der Velden J, de Boer RA, van Tintelen JP, Asselbergs FW, and Baas AF
- Subjects
- Humans, Cross-Sectional Studies, Phenotype, Biomarkers, Mutation, Cardiomyopathy, Hypertrophic diagnostic imaging, Cardiomyopathy, Hypertrophic genetics
- Abstract
Hypertrophic cardiomyopathy (HCM) is a relatively common genetic heart disease characterised by myocardial hypertrophy. HCM can cause outflow tract obstruction, sudden cardiac death and heart failure, but severity is highly variable. In this exploratory cross-sectional study, circulating acylcarnitines were assessed as potential biomarkers in 124 MYBPC3 founder variant carriers (59 with severe HCM, 26 with mild HCM and 39 phenotype-negative [G + P-]). Elastic net logistic regression identified eight acylcarnitines associated with HCM severity. C3, C4, C6-DC, C8:1, C16, C18 and C18:2 were significantly increased in severe HCM compared to G + P-, and C3, C6-DC, C8:1 and C18 in mild HCM compared to G + P-. In multivariable linear regression, C6-DC and C8:1 correlated to log-transformed maximum wall thickness (coefficient 5.01, p = 0.005 and coefficient 0.803, p = 0.007, respectively), and C6-DC to log-transformed ejection fraction (coefficient -2.50, p = 0.004). Acylcarnitines seem promising biomarkers for HCM severity, however prospective studies are required to determine their prognostic value., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
46. Physical and Psychological Child and Adult Sex Cues and Their Association with Sexual Age Preferences.
- Author
-
Lehmann RJB, Schäfer T, Fleischhauer M, Schmidt AF, and Amelung T
- Abstract
This study combined research on human mate preferences and attraction to physical and psychological features of children. Specifically, we used the Ideals Standards Model (ISM) as a conceptual framework to investigate the sexual relevance of adult and child sex cues within the general population. A sample of 589 men (mean age 30.6 years, SD = 16.6) answered questions about their sexual age preferences as well as different child and adult sex cues. The sample showed the full gamut of sexual age preferences (i.e. ranging from prepubescent children to adults over sixty years of age). A principal component analysis revealed five dimensions of adult and child sex cues. Sexual interest in children was positively related to the two dimensions of attraction to neotenous innocence and attraction to neotenous physical appearance while being negatively related to the factor of agency . In contrast, sexual interest in adults was indicated by the dimension of vitality . The fifth dimension of warmth-truthfulness was neither related to sexual interest in children nor sexual interest in adults. We argue that attraction to neotenous innocence and attraction to neotenous physical appearance can be used as an indicator of sexual interest in children. Moreover, we discuss how our results fit in with theoretical notions from the ISM.
- Published
- 2023
- Full Text
- View/download PDF
47. Protective role of CXCR7 activation in neonatal hyperoxia-induced systemic vascular remodeling and cardiovascular dysfunction in juvenile rats.
- Author
-
Benny M, Sharma M, Kulandavelu S, Chen P, Tian R, Ballengee S, Huang J, Levine AF, Claure M, Schmidt AF, Vazquez-Padron RI, Rodrigues CO, Wu S, Velazquez OC, and Young KC
- Subjects
- Animals, Humans, Rats, Animals, Newborn, Endothelial Cells, Fibrosis, Pulse Wave Analysis, Rats, Sprague-Dawley, Transforming Growth Factor beta1, Vascular Remodeling, Hyperoxia complications, Ventricular Dysfunction, Left
- Abstract
Neonatal hyperoxia induces long-term systemic vascular stiffness and cardiovascular remodeling, but the mechanisms are unclear. Chemokine receptor 7 (CXCR7) represents a key regulator of vascular homeostasis and repair by modulating TGF-β1 signaling. This study investigated whether pharmacological CXCR7 agonism prevents neonatal hyperoxia-induced systemic vascular stiffness and cardiac dysfunction in juvenile rats. Newborn Sprague Dawley rat pups assigned to room air or hyperoxia (85% oxygen), received CXCR7 agonist, TC14012 or placebo for 3 weeks. These rat pups were maintained in room air until 6 weeks when aortic pulse wave velocity doppler, cardiac echocardiography, aortic and left ventricular (LV) fibrosis were assessed. Neonatal hyperoxia induced systemic vascular stiffness and cardiac dysfunction in 6-week-old rats. This was associated with decreased aortic and LV CXCR7 expression. Early treatment with TC14012, partially protected against neonatal hyperoxia-induced systemic vascular stiffness and improved LV dysfunction and fibrosis in juvenile rats by decreasing TGF-β1 expression. In vitro, hyperoxia-exposed human umbilical arterial endothelial cells and coronary artery endothelial cells had increased TGF-β1 levels. However, treatment with TC14012 significantly reduced the TGF-β1 levels. These results suggest that dysregulation of endothelial CXCR7 signaling may contribute to neonatal hyperoxia-induced systemic vascular stiffness and cardiac dysfunction., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
48. A Reduction in Antenatal Steroid Dose Was Associated with Reduced Cardiac Dysfunction in a Sheep Model of Pregnancy.
- Author
-
Kumagai Y, Kemp MW, Usuda H, Takahashi T, Takahashi Y, Hamada H, Schmidt AF, Hanita T, Watanabe S, Sato S, Ikeda H, Fee EL, Furfaro L, Newnham JP, Jobe AH, Yaegashi N, and Saito M
- Subjects
- Sheep, Female, Pregnancy, Animals, Fetal Organ Maturity, Adrenal Cortex Hormones, Steroids, Fetal Heart diagnostic imaging, Betamethasone, Heart Diseases drug therapy
- Abstract
Despite widespread use, dosing regimens for antenatal corticosteroid (ACS) therapy are poorly unoptimized. ACS therapy exerts a programming effect on fetal development, which may be associated with an increased risk of cardiovascular disease. Having demonstrated that low-dose steroid therapy is an efficacious means of maturing the preterm lung, we hypothesized that a low-dose steroid exposure would exert fewer adverse functional and transcriptional changes on the fetal heart. We tested this hypothesis using low-dose steroid therapy (10 mg delivered to the ewe over 36 h via constant infusion) and compared cardiac effects with those of a higher dose treatment (30 mg delivered to the ewe over 24 h by intramuscular injection; simulating currently employed clinical ACS regimens). Fetal cardiac function was assessed by ultrasound on the day of ACS treatment initiation. Transcriptomic analyses were performed on fetal myocardial tissue. Relative to saline control, fetuses in the higher-dose clinical treatment group had significantly lower ratios between early diastolic ventricular filling and ventricular filling during atrial systole, and showed the differential expression of myocardial hypertrophy-associated transcripts including βMHC, GADD45γ, and PPARγ. The long-term implications of these changes remain unstudied. Irrespective, optimizing ACS dosing regimens to maximize respiratory benefit while minimizing adverse effects on key organ systems, such as the heart, offers a means of improving the acute and long-term outcomes associated with this important obstetric therapy., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
49. Exploring the Role of Plasma Lipids and Statin Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
- Author
-
Almramhi MM, Finan C, Storm CS, Schmidt AF, Kia DA, Coneys R, Chopade S, Hingorani AD, and Wood NW
- Subjects
- Humans, Cholesterol, LDL, Triglycerides, Mendelian Randomization Analysis, Cholesterol, Cholesterol, HDL, rho GTP-Binding Proteins genetics, Genome-Wide Association Study, Polymorphism, Single Nucleotide, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Multiple Sclerosis epidemiology, Multiple Sclerosis genetics
- Abstract
Background and Objectives: There has been considerable interest in statins because of their pleiotropic effects beyond their lipid-lowering properties. Many of these pleiotropic effects are predominantly ascribed to Rho small guanosine triphosphatases (Rho GTPases) proteins. We aimed to genetically investigate the role of lipids and statin interventions on multiple sclerosis (MS) risk and severity., Method: We used two-sample Mendelian randomization (MR) to investigate (1) the causal role of genetically mimic both cholesterol-dependent (through low-density lipoprotein cholesterol (LDL-C) and cholesterol biosynthesis pathway) and cholesterol-independent (through Rho GTPases) effects of statins on MS risk and MS severity, (2) the causal link between lipids (high-density lipoprotein cholesterol [HDL-C] and triglycerides [TG]) levels and MS risk and severity, and (3) the reverse causation between lipid fractions and MS risk. We used summary statistics from the Global Lipids Genetics Consortium (GLGC), eQTLGen Consortium, and the International MS Genetics Consortium (IMSGC) for lipids, expression quantitative trait loci, and MS, respectively (GLGC: n = 188,577; eQTLGen: n = 31,684; IMSGC (MS risk): n = 41,505; IMSGC (MS severity): n = 7,069)., Results: The results of MR using the inverse-variance weighted method show that genetically predicted RAC2 , a member of cholesterol-independent pathway (OR 0.86 [95% CI 0.78-0.95], p -value 3.80E-03), is implicated causally in reducing MS risk. We found no evidence for the causal role of LDL-C and the member of cholesterol biosynthesis pathway on MS risk. The MR results also show that lifelong higher HDL-C (OR 1.14 [95% CI 1.04-1.26], p -value 7.94E-03) increases MS risk but TG was not. Furthermore, we found no evidence for the causal role of lipids and genetically mimicked statins on MS severity. There is no evidence of reverse causation between MS risk and lipids., Discussion: Evidence from this study suggests that RAC2 is a genetic modifier of MS risk. Because RAC2 has been reported to mediate some of the pleiotropic effects of statins, we suggest that statins may reduce MS risk through a cholesterol-independent pathway (that is, RAC2-related mechanism(s)). MR analyses also support a causal effect of HDL-C on MS risk., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)
- Published
- 2023
- Full Text
- View/download PDF
50. Identifying and ranking novel independent features for cardiovascular disease prediction in people with type 2 diabetes.
- Author
-
Dziopa K, Chaturvedi N, Asselbergs FW, and Schmidt AF
- Abstract
Background: CVD prediction models do not perform well in people with diabetes. We therefore aimed to identify novel predictors for six facets of CVD, (including coronary heart disease (CHD), Ischemic stroke, heart failure (HF), and atrial fibrillation (AF)) in people with T2DM., Methods: Analyses were conducted using the UK biobank and were stratified on history of CVD and of T2DM: 459,142 participants without diabetes or a history of CVD, 14,610 with diabetes but without CVD, and 4,432 with diabetes and a history of CVD. Replication was performed using a 20% hold-out set, ranking features on their permuted c-statistic., Results: Out of the 600+ candidate features, we identified a subset of replicated features, ranging between 32 for CHD in people with diabetes to 184 for CVD+HF+AF in people without diabetes. Classical CVD risk factors (e.g. parental or maternal history of heart disease, or blood pressure) were relatively highly ranked for people without diabetes. The top predictors in the people with diabetes without a CVD history included: cystatin C, self-reported health satisfaction, biochemical measures of ill health (e.g. plasma albumin). For people with diabetes and a history of CVD top features were: self-reported ill health, and blood cell counts measurements (e.g. red cell distribution width). We additionally identified risk factors unique to people with diabetes, consisting of information on dietary patterns, mental health and biochemistry measures. Consideration of these novel features improved risk classification, for example per 1000 people with diabetes 133 CVD and 165 HF cases appropriately received a higher risk., Conclusion: Through data-driven feature selection we identified a substantial number of features relevant for prediction of cardiovascular risk in people with diabetes, the majority of which related to non-classical risk factors such as mental health, general illness markers, and kidney disease., Competing Interests: Conflict of interest statement NC serves on data safety and monitoring committees of clinical trials sponsored by AstraZeneca. AFS has received funding from New Amsterdam Pharma for unrelated work. None of the other authors of this paper has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the content of the paper.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.